[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 296
1. Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP, Avramis VI: Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood; 2007 Apr 1;109(7):2744-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.
  • We administered a single intravenous dose of pegaspargase (2000 IU/m2) as part of a standard frontline induction regimen to 25 adults with newly diagnosed acute lymphoblastic leukemia (ALL), and obtained serum samples on several time points.
  • After the single dose, asparagine deamination was complete in all patients after 2 hours, and in 100%, 81%, and 44% on days 14, 21, and 28, respectively.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Asparaginase / pharmacology. Polyethylene Glycols / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Clinical Protocols. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Remission Induction / methods. Safety. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17132721.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


2. Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB, Shuster JJ, Children's Oncology Study Group: Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol; 2007 Sep;29(9):627-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
  • We describe the outcome of children with B-precursor acute lymphoblastic leukemia registered on Pediatric Oncology Group 8602 who switched to Erwinia asparaginase (ASP) due to an allergy to the Escherichia coli product.
  • Between February 1986 and January 1991, children in complete remission after induction that included intramuscular E. coli ASP (6000 U/m2x6) were randomized for consolidation.
  • Allergic reactions were significantly associated with younger age, white race, and standard-risk acute lymphoblastic leukemia.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Erwinia / enzymology. Humans. Infant. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Allergy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2007 Sep;29(9):587-8 [17805029.001]
  • (PMID = 17805038.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-03161; United States / NCI NIH HHS / CA / CA-05587; United States / NCI NIH HHS / CA / CA-07431; United States / NCI NIH HHS / CA / CA-11233; United States / NCI NIH HHS / CA / CA-15525; United States / NCI NIH HHS / CA / CA-15898; United States / NCI NIH HHS / CA / CA-15989; United States / NCI NIH HHS / CA / CA-20549; United States / NCI NIH HHS / CA / CA-25408; United States / NCI NIH HHS / CA / CA-28383; United States / NCI NIH HHS / CA / CA-28439; United States / NCI NIH HHS / CA / CA-28476; United States / NCI NIH HHS / CA / CA-29139; United States / NCI NIH HHS / CA / CA-29293; United States / NCI NIH HHS / CA / CA-29691; United States / NCI NIH HHS / CA / CA-30969; United States / NCI NIH HHS / CA / CA-31566; United States / NCI NIH HHS / CA / CA-32053; United States / NCI NIH HHS / CA / CA-33587; United States / NCI NIH HHS / CA / CA-33603; United States / NCI NIH HHS / CA / CA-33625; United States / NCI NIH HHS / CA / CA-53128; United States / NCI NIH HHS / CA / CA-69177; United States / NCI NIH HHS / CA / CA-69428
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


3. Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan AK, Litzow MR, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH: Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood; 2009 May 07;113(19):4489-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.
  • Prospective data on the value of allogeneic hematopoietic stem cell transplantation (alloHSCT) in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) are limited.
  • The UKALLXII/ECOG 2993 study evaluated the outcome of assigning alloHSCT with a sibling (sib) or matched unrelated donor (MUD) to patients younger than 55 years of age achieving complete remission (CR).
  • This prospective trial in adult Ph(+) ALL indicates a modest but significant benefit to alloHSCT.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Philadelphia Chromosome. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Benzamides. Female. Humans. Imatinib Mesylate. Immunophenotyping. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Prognosis. Prospective Studies. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. RNA, Messenger / genetics. RNA, Messenger / metabolism. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1991 Mar;5(3):196-9 [2013979.001]
  • [Cites] Blood. 1987 Aug;70(2):587-8 [3300815.001]
  • [Cites] Am J Med. 1994 Jul;97(1):60-5 [8030658.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Bone Marrow Transplant. 1995 Nov;16(5):663-7 [8547863.001]
  • [Cites] Blood. 2005 Jul 15;106(2):458-63 [15817679.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1410-4 [9269758.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):365-9 [8704688.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):489-500 [16098062.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Ann Hematol. 2006 Jun;85(6):366-73 [16523310.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Cancer. 2007 May 15;109(10):2068-76 [17429836.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2309-15 [17496201.001]
  • [Cites] Haematologica. 2008 Feb;93(2):287-90 [18223280.001]
  • [Cites] Haematologica. 2008 Feb;93(2):303-6 [18245655.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Blood. 2008 Aug 1;112(3):903-9 [18519812.001]
  • [Cites] Blood. 2009 Jan 1;113(1):100-7 [18838613.001]
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):263-73 [10674898.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1536-43 [11861265.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(9):763-6 [12732882.001]
  • [Cites] Br J Haematol. 2004 Feb;124(3):275-88 [14717774.001]
  • [Cites] Blood. 1987 Apr;69(4):1015-20 [3548841.001]
  • [Cites] Blood. 1992 Jun 1;79(11):3067-70 [1586748.001]
  • (PMID = 19244158.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN77346223; ClinicalTrials.gov/ NCT00002514
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U24 CA114737
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC4188540
  •  go-up   go-down


Advertisement
4. Ebeid EN, Kamel MM, Ali BA: Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma. J Egypt Natl Canc Inst; 2008 Jun;20(2):127-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
  • BACKGROUND: Asparaginase is an effective antileukemic agent which is included in most front-line protocols for pediatric acute lymphoblastic leukemia (ALL) worldwide.
  • PURPOSE: The aim of this study was to determine if the presence of antibodies during induction and continuation phases in newly diagnosed children with ALL and lymphoblastic lymphoma during therapy with E.coli asparaginase, had any correlation with various factors such as: age, gender, hypersensitivity reactions, response to therapy and Event Free Survival (EFS).
  • Forty children had newly diagnosed ALL and 24 had lymphoblastic lymphoma.
  • RESULTS: Forty one patients achieved complete remission, 9 had partial remission, and 14 were lost to followup at different intervals of treatment.
  • CONCLUSIONS: The presence of antiasparaginase antibodies was unrelated to age, gender, hypersensitivity reaction, response to therapy and event free survival of newly diagnosed children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
  • [MeSH-major] Antibodies, Anti-Idiotypic / blood. Antineoplastic Agents / therapeutic use. Asparaginase / therapeutic use. Escherichia coli / enzymology. Leukemia, Lymphoid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibody Formation. Child. Child, Preschool. Drug Hypersensitivity. Female. Humans. Male. Prognosis. Remission Induction. Sex Factors. Survival Rate. Treatment Outcome. Young Adult


5. Terwey TH, Kim TD, Arnold R: Allogeneic hematopoietic stem cell transplantation for adult acute lymphocytic leukemia. Curr Hematol Malig Rep; 2009 Jul;4(3):139-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation for adult acute lymphocytic leukemia.
  • Allogeneic hematopoietic stem cell transplantation (alloHCT) is the single most potent treatment modality to prevent relapse in adults with acute lymphocytic leukemia, but its optimal use and timing remains a matter of intense debate and research.
  • There is general agreement that patients with clinical features of high risk for relapse should undergo alloHCT in first complete remission.
  • AlloHCT also offers the only reasonable chance for cure in Philadelphia chromosome-positive acute lymphocytic leukemia; the role of imatinib is not yet clearly defined.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adult. Humans. Neoplasm, Residual / prevention & control. Prognosis. Risk Assessment. Time Factors. Transplantation, Homologous. Treatment Outcome


6. Advani AS, Jin T, Ramsingh G, Tiu R, Saber W, Theil K, Sobecks R, Sekeres M, Copelan E, Sungren S, Tripp B, Kalaycio M: Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. Leuk Lymphoma; 2008 Aug;49(8):1560-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia.
  • Cox proportional hazards analysis was used to identify univariate and multivariate correlates of complete remission, overall survival and progression-free survival.
  • On univariate analysis, significant prognostic factors included: age at diagnosis (per 10-year increase), poor risk cytogenetics, time to white blood count recovery, and time from induction chemotherapy (IC) to post-remission therapy (PRT).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Cytogenetic Analysis. Humans. Middle Aged. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766970.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M: Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant; 2008 May;14(5):568-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
  • We retrospectively evaluated the outcomes of 37 adult patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT) conditioned with medium-dose VP-16 (VP, 30 mg/kg), cyclophosphamide (CY, 120 mg/kg), and fractionated total-body irradiation (TBI, 12 Gy) (medium-dose VP/CY/TBI).
  • Ten patients were Philadelphia chromosome-positive (Ph(+)) and 35 patients were in complete remission (CR) at transplantation.
  • Grade II-III acute graft-versus-host disease (GVHD) and chronic GVHD (cGVHD) occurred in 15 and 18 patients, respectively.
  • No patient developed grade IV acute GVHD (aGVHD) or died of GVHD.
  • Medium-dose VP/CY/TBI for adult ALL patients was associated with lower relapse rate and no increase in toxicity, resulting in better survival.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Graft vs Host Disease. Humans. Male. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410899.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


8. Steinherz PG, Shukla N, Kobos R, Steinherz L: Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer; 2010 May;54(5):687-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
  • BACKGROUND: We determined the maximum tolerated dose (MTD) of clofarabine when administered with topotecan, vinorelbine, thiotepa, and dexamethasone (TVTC) for children with relapsed or refractory acute leukemia, and observed the efficacy and toxicities of this therapy.
  • PROCEDURE: Twelve patients with acute lymphoblastic or myeloblastic leukemia were given a 14-day remission induction therapy.
  • Patients who achieved a remission proceeded to a stem cell transplant (HSCT).
  • RESULTS: Of the six patients at the 30 mg/m(2) clofarabine dose, two achieved a complete response (CR) and one a PR and proceeded to BMT.
  • One patient died on day 45 with marrow hypoplasia without evidence of leukemia.
  • CONCLUSION: TVTC has significant anti-leukemic activity in both acute lymphoblastic and myeloblastic leukemia.
  • This is the recommended dose for the phase II study in patients with refractory or relapsed leukemia, a population which has limited therapeutic options.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy
  • [MeSH-minor] Adenine Nucleotides / administration & dosage. Adenine Nucleotides / adverse effects. Adolescent. Adult. Arabinonucleosides / administration & dosage. Arabinonucleosides / adverse effects. Child. Child, Preschool. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Hematopoietic Stem Cell Transplantation. Humans. Infant. Male. Maximum Tolerated Dose. Recurrence. Remission Induction. Thiotepa / administration & dosage. Thiotepa / adverse effects. Topotecan / administration & dosage. Topotecan / adverse effects. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205253.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 5V9KLZ54CY / Vinblastine; 762RDY0Y2H / clofarabine; 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; Q6C979R91Y / vinorelbine
  •  go-up   go-down


9. Ma Y, Chen B, Xu X, Lin G: Myeloid/natural killer cell precursor acute leukemia with multiple subcutaneous nodules as the initial presentation: a case report and literature review. Int J Hematol; 2009 Sep;90(2):243-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid/natural killer cell precursor acute leukemia with multiple subcutaneous nodules as the initial presentation: a case report and literature review.
  • Myeloid/natural killer (NK) cell precursor acute leukemia is a rare neoplasm, which is characterized by high incidence of extramedullary infiltration, especially in the mediastinum and lymph nodes, an aggressive course and poor prognosis.
  • As coexpressing myeloid and NK-cell antigens, myeloid/NK-cell precursor acute leukemia (MNKL) may pose diagnostic difficulty.
  • Although bone marrow achieved complete remission using DA chemotherapeutic regimen, the skin nodules did not regress.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia, Myeloid / pathology. Myeloid Cells / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Skin / pathology
  • [MeSH-minor] Bone Marrow / pathology. Diagnosis, Differential. Humans. Leukemic Infiltration. Male. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Haematol. 2002;108(1):47-52 [12145468.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):149-53 [12953810.001]
  • [Cites] Ann Hematol. 2005 Sep;84(9):616-8 [15782344.001]
  • [Cites] Br J Haematol. 2007 Nov;139(4):532-44 [17916099.001]
  • [Cites] Int J Hematol. 2002 Feb;75(2):201-6 [11939270.001]
  • [Cites] Leuk Res. 2002 Feb;26(2):215-9 [11755472.001]
  • [Cites] Leuk Res. 1996 Nov-Dec;20(11-12):983-5 [9009257.001]
  • [Cites] Int J Hematol. 2004 Jan;79(1):92-4 [14979485.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):764-7 [18401411.001]
  • [Cites] Leuk Lymphoma. 2008 Feb;49(2):342-5 [18231923.001]
  • [Cites] Arch Pathol Lab Med. 2004 Aug;128(8):e100-3 [15270596.001]
  • [Cites] Blood. 1994 Jul 1;84(1):244-55 [7517211.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2622-4 [9516168.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1232-8 [10914547.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2036-8 [15483671.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):768-72 [18401412.001]
  • [Cites] Ann Hematol. 2004 Jun;83(6):345-8 [15014900.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1425-36 [18286525.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):868-71 [10414508.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2417-28 [9310493.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1209-16 [11493472.001]
  • [Cites] Br J Haematol. 2001 Jan;112(1):127-37 [11167793.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):684-5 [12139765.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(4):425-31 [16400344.001]
  • [Cites] Haematologica. 2000 Mar;85(3):322-4 [10702827.001]
  • [Cites] Ann Hematol. 2001 Jan;80(1):58-61 [11233779.001]
  • [Cites] Am J Hematol. 2003 Sep;74(1):46-51 [12949889.001]
  • [Cites] Leuk Res. 1999 Jul;23(7):615-24 [10400182.001]
  • [Cites] Ann Hematol. 2004 Dec;83(12):784-8 [15322764.001]
  • [Cites] Hum Pathol. 2003 May;34(5):504-8 [12792926.001]
  • [Cites] Pathology. 2003 Aug;35(4):325-9 [12959763.001]
  • [Cites] Annu Rev Immunol. 2006;24:287-320 [16551251.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Dec;163(2):156-9 [16337859.001]
  • (PMID = 19639272.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 34
  •  go-up   go-down


10. Seiter K, Katragadda S, Ponce D, Rasul M, Ahmed N: Temozolomide and cisplatin in relapsed/refractory acute leukemia. J Hematol Oncol; 2009;2:21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide and cisplatin in relapsed/refractory acute leukemia.
  • Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide.
  • We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia.
  • Fifteen patients had AML, 3 had ALL, and 2 had biphenotypic leukemia.
  • There was one complete remission in this heavily pretreated patient population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Dacarbazine / analogs & derivatives. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Resistance, Neoplasm / drug effects. Female. Humans. Male. Middle Aged. Recurrence. Salvage Therapy. Treatment Failure. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):735-41 [9816224.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):547-54 [15973664.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2007 Apr;21(4):821-4 [17252015.001]
  • [Cites] DNA Repair (Amst). 2007 Aug 1;6(8):1179-86 [17500047.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2756-60 [17948909.001]
  • [Cites] Anticancer Drugs. 1992 Aug;3(4):401-5 [1421437.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):5846-52 [3664486.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1974 Mar;7(3):529-38 [4824827.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3249-53 [12149298.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Aug;294(2):664-71 [10900246.001]
  • [Cites] Leukemia. 2000 Mar;14(3):476-9 [10720145.001]
  • [Cites] Ann Oncol. 1995 Apr;6(4):389-93 [7619755.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2933-6 [9230204.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Oct;279(1):416-22 [8859021.001]
  • [Cites] Biochem Pharmacol. 1996 May 3;51(9):1221-8 [8645346.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1888-95 [7475280.001]
  • [Cites] J Chemother. 1995 Jun;7(3):224-9 [7562019.001]
  • [Cites] Leukemia. 1995 Jul;9(7):1126-9 [7630183.001]
  • [Cites] Mol Pharmacol. 1998 Aug;54(2):334-41 [9687575.001]
  • (PMID = 19463179.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2694825
  •  go-up   go-down


11. Candoni A, Michelutti A, Simeone E, Damiani D, Baccarani M, Fanin R: Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins. Eur J Haematol; 2006 Oct;77(4):293-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
  • The treatment of relapsed adult acute lymphoblastic leukaemia (ALL) is frequently unsuccessful with current chemotherapy regimens, and often there is an overexpression of multidrug resistance (MDR)-related proteins.
  • Twenty pts (80%) achieved a complete remission (CR) and two (8%) entered a partial remission (PR) for an overall response (OR) rate of 88% (22/25), with a tolerable toxicity and without significant cardiotoxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multidrug Resistance-Associated Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Liposomes. Male. Middle Aged. Recurrence

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856922.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Liposomes; 0 / Multidrug Resistance-Associated Proteins; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


12. Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, Steele D, Zipf T, Stram DO, Villaluna D, Trigg ME: Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol; 2006 Jul 1;24(19):3150-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
  • PURPOSE: To compare conventional sibling bone marrow transplantation (CBMT), BMT with alternative donor (ABMT), and chemotherapy (CT) for children with acute lymphoblastic leukemia (ALL) and an early first marrow relapse.
  • One hundred sixty-three patients with fewer than 25% marrow blasts and count recovery at the end of induction (second remission [CR2]) were allocated by donor availability.
  • BMT is not a complete answer to the challenge of ALL and early marrow relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / surgery. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Siblings. Survival Analysis. Transplantation, Homologous. Treatment Outcome


13. Kang W, Hahn JS, Kim JS, Cheong JW, Yang WI: Nine-year survival of lymphoblastic lymphoma patients. Yonsei Med J; 2006 Aug 31;47(4):466-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nine-year survival of lymphoblastic lymphoma patients.
  • This study aimed to analyze the overall survival period of adult lymphoblastic lymphoma patients treated with various therapeutic regimens, and to assess the determinants affecting survival outcome.
  • Twenty-five adult patients with lymphoblastic lymphoma who had been treated at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea from June 1996 to June 2005 were analyzed retrospectively.
  • As an initial remission induction chemotherapy, the hyper-CVAD regimen was performed in eight patients, the Stanford/Northern California Oncology Group (NCOG) regimen in five, the CAVOP regimen in four, the m-BACOP regimen in three, and the CHOP regimen in one patient.
  • The overall response rate was 80% (60% showing a complete response, 20% showing a partial response) and the relapse rate was 73.3%.
  • The Stanford/NCOG regimen is an effective initial choice of therapy for lymphoblastic lymphoma patients, and is superior to the hyper-CVAD regimen in complete response rate and overall survival rate (p =0.36).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / pharmacology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Stem Cell Transplantation / methods. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood Rev. 2000 Mar;14(1):1-13 [10805257.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2927-36 [11387366.001]
  • [Cites] Ann Hematol. 2001 Nov;80(11):647-52 [11757723.001]
  • [Cites] Cytotherapy. 2002;4(3):223-40 [12194719.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] Yonsei Med J. 1997 Oct;38(5):270-84 [9409190.001]
  • [Cites] Yonsei Med J. 2003 Oct 30;44(5):757-70 [14584090.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1628-37 [3772416.001]
  • [Cites] Semin Oncol. 1990 Feb;17(1):96-103 [2406921.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2220-4 [14576732.001]
  • (PMID = 16941734.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2687725
  •  go-up   go-down


14. López-Hernández MA, Alvarado-Ibarra M, Jiménez-Alvarado RM, De Diego-Flores JE, González-Avante CM: [Adolescents with de novo acute lymphoblastic leukemia: efficacy and safety of a pediatric vs adult treatment protocol]. Gac Med Mex; 2008 Nov-Dec;144(6):485-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adolescents with de novo acute lymphoblastic leukemia: efficacy and safety of a pediatric vs adult treatment protocol].
  • OBJECTIVE: To ascertain the efficacy and safety of two chemotherapy regimens, one designed for adults and the other for children, in adolescent patients with acute lymphoblastic leukemia (ALL).
  • Elective suspension of chemotherapy occurred at two and three years respectively, in patients with continued complete remission.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Clinical Protocols. Female. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112720.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


15. Chevallier P, Mahe B, Garand R, Talmant P, Harousseau JL, Delaunay J: Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. Int J Hematol; 2008 Sep;88(2):209-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
  • It was developed at the end of the nineties as 90% of the leukemic blast population of patients with acute myeloid leukaemia (AML) express the CD33 surface antigen (Dinndorf et al. [1] Blood 1986;67:1048-53).
  • CD33 antigen expression is also observed at diagnosis (in 15% of cases) (Pui et al. [3] J Clin Oncol 1998;16:3768-73) or at relapse (Guglielmi et al. [4] Leukemia 1997; 11:1501-7) of acute lymphoblastic leukaemia (ALL), representing a potential cellular target for ALL patients.
  • Case series have already demonstrated the efficacy of GO in children with relapsed CD33+ ALL with documentation of complete remission (CR) (Balduzzi et al. [5] Leukemia 2003;17:2247-8; Cotter et al. [6] Br J Haematol 2003;122:686-91; Zwaan et al. [7] Leukemia 2003;17:468-70).
  • In the other hand, there is no report at our knowledge of the use of GO in the setting of adult CD33+ ALL patient.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Fatal Outcome. Hematopoietic Stem Cell Transplantation. Humans. Male. Remission Induction. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2004 Nov;89(11):1399-401 [15531467.001]
  • [Cites] Leukemia. 2003 Feb;17 (2):468-70 [12592351.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3768-73 [9850020.001]
  • [Cites] Blood. 1986 Apr;67(4):1048-53 [2937468.001]
  • [Cites] Br J Haematol. 2007 Oct;139(2):344-5 [17897313.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1003-7 [16038726.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Br J Haematol. 2003 Aug;122(4):687-8 [12899727.001]
  • [Cites] Leukemia. 2004 Sep;18(9):1557-8 [15229619.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2247-8 [12960967.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1501-7 [9305605.001]
  • (PMID = 18668307.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 93NS566KF7 / gemtuzumab
  •  go-up   go-down


16. Frassoni F, Gualandi F, Podestà M, Raiola AM, Ibatici A, Piaggio G, Sessarego M, Sessarego N, Gobbi M, Sacchi N, Labopin M, Bacigalupo A: Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol; 2008 Sep;9(9):831-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study.
  • BACKGROUND: Cord-blood transplants are associated with delayed or failed engraftment in about 20% of adult patients.
  • METHODS: Adult patients with acute leukaemia, for whom an unrelated stem-cell transplantation was indicated and no suitable unrelated human leucocyte antigen (HLA)-matched donor had been identified, were included in the study and underwent a cord-blood transplant in San Martino Hospital, Genoa, Italy.
  • Eight patients were in first complete remission, ten in second complete remission, and 14 had advanced-stage, refractory disease.
  • Secondary endpoints included the incidence of acute graft-versus-host disease, relapse, and overall survival.
  • FINDINGS: Between March 31, 2006, and Jan 25, 2008, 32 consecutive patients with acute myeloid leukaemia (n=20) or acute lymphoblastic leukaemia (n=12) underwent a cord-blood transplant (median age 36 years [range 18-66]).
  • All patients were fully chimeric from 30 days after transplantation to the last follow-up visit, suggesting an early complete donor engraftment.
  • No patient developed grade III-IV acute graft-versus-host disease.
  • 16 patients were alive and in haematological remission at a median follow-up of 13 months (range 3-23).
  • INTERPRETATION: Our preliminary data suggest that direct intrabone cord-blood transplantation overcomes the problem of graft failure even when low numbers of HLA-mismatched cord-blood cells are transplanted, thus leading to the possibility of use of this technique in a large number of adult patients.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Humans. Infusions, Intraosseous. Middle Aged. Transplantation, Homologous. Treatment Outcome


17. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J: Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood; 2009 May 21;113(21):5058-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
  • Second-generation tyrosine kinase inhibitors are effective in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML).
  • Occasionally, patients with Ph(+) ALL, or accelerated phase (AP) or blast phase (BP) CML achieve a major cytogenetic response (MCyR) but not a complete hematologic response (CHR).
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Protein Kinase Inhibitors / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Benzamides. Blast Crisis. Cytogenetic Analysis. Dasatinib. Female. Humans. Imatinib Mesylate. Leukemia, Myeloid, Accelerated Phase. Male. Middle Aged. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Prognosis. Pyrimidines / administration & dosage. Remission Induction / methods. Survival Analysis. Thiazoles / administration & dosage. Treatment Failure. Young Adult

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Sep 15;108(6):1809-20 [16709930.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3207-13 [17185463.001]
  • [Cites] Blood. 2007 May 15;109(10):4143-50 [17264298.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2309-15 [17496201.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3540-6 [17715389.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):111-8 [9576191.001]
  • [Cites] Clin Adv Hematol Oncol. 2008 Feb;6(2):113-7 [18347562.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1200-6 [18401416.001]
  • [Cites] Semin Hematol. 2003 Jan;40(1):79-86 [12563614.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1033-41 [12569603.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3097-9 [12842982.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1834-9 [18048643.001]
  • (PMID = 19282457.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; RBZ1571X5H / Dasatinib
  • [Other-IDs] NLM/ PMC4081366
  •  go-up   go-down


18. Shi JM, Huang H, Chen QF, Lin MF: [Expression level of TRF1 protein in human acute leukemia and its relationship with activity of telomerase]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):858-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression level of TRF1 protein in human acute leukemia and its relationship with activity of telomerase].
  • The study was aimed to investigate the expression level of TRF1 protein in human acute leukemia and relationship between expression level of TRF1 protein and activity of telomerase.
  • 20 cases of acute leukemias were studied when 11 normal volunteer's bone marrow was used as control.
  • The results showed that the expression level of TRF1 protein in normal bone marrow (2.217 +/- 0.461 microg/microl) was significantly higher than that in bone marrow of acute leukemia patients (0.754 +/- 0.343 microg/microl) (P < 0.01).
  • After chemotherapy, TRF1 expression level of patients with complete remission raised (0.772 +/- 0.307 microg/microl vs 1.683 +/- 0.344 microg/microl, P < 0.01), but lower than that of normal (2.217 +/- 0.461 microg/microl, P < 0.01).
  • TRF1 expression level of patients without complete remission was not remarkable different after chemotherapy (0.726 +/- 0.443 microg/microl vs 0.894 +/- 0.338 microg/microl, P > 0.05).
  • TRF1 expression level of patients with complete remission was higher than that in patients without complete remession (1.683 +/- 0.344 microg/microl vs 0.894 +/- 0.338 microg/microl, P < 0.01).
  • It was confirmed that the activity of telomerase in normal bone marrow was lower than that in bone marrow of acute leukemia patients (0.125 +/- 0.078 microg/microl vs 0.765 +/- 0.284 microg/microl, P < 0.01).
  • After chemotherapy, telomerase activity of patients with complete remission reduced (0.393 +/- 0.125 microg/microl), but higher than that of normal (0.125 +/- 0.078 microg/microl, P < 0.01).

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096876.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Telomeric Repeat Binding Protein 1; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


19. Cimino G, Cenfra N, Elia L, Sica S, Luppi M, Meloni G, Vignetti M, Paoloni F, Foà R, Mandelli F: The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience. Haematologica; 2010 May;95(5):837-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience.
  • The clinical outcome of 21 adults with ALL1(MLL)/AF4 positive acute lymphoblastic leukemia enrolled in the GIMEMA LAL 2000 trial and of 25 patients entered into the previous 0496 study is reported.
  • Complete remission rates were 90% and 88% in the LAL 2000 and 0496 trials, respectively.
  • [MeSH-major] Biomarkers, Tumor / genetics. DNA-Binding Proteins / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Nuclear Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cohort Studies. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Histone-Lysine N-Methyltransferase. Humans. Male. Middle Aged. Oncogene Proteins, Fusion. Remission Induction. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2014-20 [12791662.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10735-9 [1720549.001]
  • [Cites] Cell. 1992 Nov 13;71(4):691-700 [1423624.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2155-61 [17039234.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Cell. 1992 Nov 13;71(4):701-8 [1423625.001]
  • [Cites] Nat Genet. 1992 Oct;2(2):113-8 [1303259.001]
  • [Cites] Blood. 1993 Jul 15;82(2):544-6 [8329709.001]
  • [Cites] Blood. 1993 Nov 15;82(10):2943-7 [8219184.001]
  • [Cites] N Engl J Med. 1994 Feb 3;330(5):328-36 [8277954.001]
  • [Cites] Baillieres Clin Haematol. 1994 Jun;7(2):235-62 [7803900.001]
  • [Cites] Leukemia. 1995 Mar;9(3):391-5 [7885037.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1898-909 [9731046.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):417-20 [12124171.001]
  • (PMID = 20107154.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 150826-18-9 / AFF1 protein, human; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Other-IDs] NLM/ PMC2864392
  •  go-up   go-down


20. Li QH, DU X, Huang ZL, Luo CW, Zhong LY, Lin W: [Therapeutic effects of chemotherapeutic regimens containing pirarubicin on the treatment of high-risk or refractory and relapsed acute leukemia in adults]. Zhonghua Yi Xue Za Zhi; 2005 May 11;85(17):1195-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic effects of chemotherapeutic regimens containing pirarubicin on the treatment of high-risk or refractory and relapsed acute leukemia in adults].
  • OBJECTIVE: To evaluate the therapeutic effects of chemotherapeutic regimen containing pirarubicin (THP) on the treatment of high-risk or refractory and relapsed acute leukemia (AL) in adults.
  • METHODS: Forty patients with high-risk or refractory and relapsed AL, 26 males and 14 females, aged 33 (14-63) received treatment regimens with THP: TA regimen [THP + cytosine-arabinoside (Ara-C)] for acute myeloid leukemia (AML) and TAOP regimen [THP + Ara-C + vincristine (VCR) + prednisone (Pred)] for acute lymphocytic leukemia (ALL) or biphenotype-AL.
  • RESULTS: The complete remission (CR) rate was 47.5% vs 45% (P > 0.05), partial response (PR) rate was 25% vs 20% (P > 0.05), and overall response (OR) rate was 72.5% vs 65% (P > 0.05) in the treatment group and control group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cytarabine / administration & dosage. Female. Humans. Male. Middle Aged. Recurrence. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029595.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


21. Zhang ZM, Xie ZX, Tan DR, Huang CH: [Detection of glutathione S-transferase and lung resistance-related proteins in acute leukemia and its clinical significance]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Jun;30(3):292-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of glutathione S-transferase and lung resistance-related proteins in acute leukemia and its clinical significance].
  • OBJECTIVE: To explore the relationship among intracellular glutathione S-transferase activity (GST), the expression of lung resistance-related proteins (LRP) in acute leukemia, and its clinical effects.
  • METHODS: The GST activity of bone marrow mononuclear cells and LRP expression in 57 acute leukemia patients were detected by the spectrophotometry assay and immuno-cytochemistry (SABC), respectively.
  • RESULTS: The GST activity of bone marrow mononuclear cells in the acute leukemia group was significantly higher than that of the control group (P < 0.01).
  • The GST activity of mononuclear cells in acute leukemia was positively correlated with the percentage of blast in the bone marrow (r = 0.30, P < 0.05).
  • The GST activity of mononuclear cells in the untreated acute leukemia group was obviously higher than that of the complete remission group (P <0.01).
  • The GST activity in the refractory or relapsed acute leukemia group was significantly higher than that of the complete remission group and untreated leukemia group (P <0.05).
  • In post-chemotherapy 13 of 17 the LRP-positive patients were the non-remission, 12 of the 20 LRP-negative patients were the complete remission.
  • The GST activities of non-remission patients in the LRP-positive and LRP-negative group obviously increased.
  • CONCLUSION: The increase of GST activity in the bone marrow mononuclear cells is related to the clinical curative effects and the proliferation of blast in acute leukemia.
  • Detection of LRP and GST activities in acute leukemia may have a reference value in judging the leukemia with drug resistance and estimating the prognosis.
  • [MeSH-major] Glutathione Transferase / metabolism. Leukemia, Myeloid, Acute / metabolism. Neoplasm Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vault Ribonucleoprotein Particles / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Cells / metabolism. Child. Female. Humans. Male. Middle Aged. Multidrug Resistance-Associated Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045016.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


22. Yao L, Chen ZX, Cen JN, Liu H, He J, Wu DP: [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection]. Zhonghua Xue Ye Xue Za Zhi; 2010 Jul;31(7):433-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
  • OBJECTIVE: To explore detection of immunoglobulin heavy chain gene (IgH) rearrangement by real-time quantitative polymerase chain reaction (RQ-PCR) for minimal residual disease (MRD) monitoring in adult B-lineage acute lymphoblastic leukemia (B-ALL) patients.
  • METHODS: DNA samples of fifteen newly diagnosed adult B-ALL patients were collected.
  • RESULTS: The detection sensitivity of ASO-PCR varied between 10(-3) and 10(-5) leukemia cells in 15 adult ALL patients.
  • Quantification monitoring MRD showed that high-risk adult ALL patients in complete remission (CR) had a higher MRD level than those of standard-risk.
  • These data indicates a close correlation between the level of rearranged IgH and the treatment response and prognosis in adult ALL patients.
  • [MeSH-major] Neoplasm, Residual. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. DNA Primers. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulins / therapeutic use. Polymerase Chain Reaction. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122394.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulins
  •  go-up   go-down


23. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, Réa D, Cayuela JM, Vekemans MC, Reman O, Buzyn A, Pigneux A, Escoffre M, Chalandon Y, MacIntyre E, Lhéritier V, Vernant JP, Thomas X, Ifrah N, Dombret H, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL): Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood; 2007 Feb 15;109(4):1408-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
  • The combination of imatinib with chemotherapy has been recently reported as very promising in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
  • During 2004 and 2005, 45 patients with newly diagnosed Ph+ ALL were treated in the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAAPH) 2003 study, in which imatinib was started with HAM (mitoxantrone with intermediate-dose cytarabine) consolidation in good early responders (corticosensitive and chemosensitive ALL) or earlier during the induction course in combination with dexamethasone and vincristine in poor early responders (corticoresistant and/or chemoresistant ALL).
  • Overall, complete remission (CR) and BCR-ABL real-time quantitative polymerase chain reaction (RQ-PCR) negativity rates were 96% and 29%, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Philadelphia Chromosome. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Benzamides. Cytarabine / therapeutic use. Female. Hematopoietic Stem Cell Transplantation. Humans. Imatinib Mesylate. Male. Middle Aged. Mitoxantrone / therapeutic use. Neoplasm, Residual. Remission Induction. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062730.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 04079A1RDZ / Cytarabine; 8A1O1M485B / Imatinib Mesylate; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


24. Li AH, Qiu GQ, Gu WY, Ling Y, Weng KZ, Tan Q, Cao XS: [Expression of CD4+ CD25+ regulatory T cells in the patients with acute lymphocytic leukemia]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 May;23(5):439-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of CD4+ CD25+ regulatory T cells in the patients with acute lymphocytic leukemia].
  • AIM: To evaluate the proportion of CD4(+) CD25(+) Tregs in the peripheral blood of the patients suffering from acute lymphocytic leukemia (ALL) with or without chemotherapy and investigate whether the serum from patients could convert peripheral CD4(+) CD25(-) T cells to CD4(+) CD25(+) Tregs.
  • METHODS: The proportion of CD4(+) CD25(+) T cells in the peripheral blood of three groups of people (the patients with ALL before therapy, the patients with ALL who achieved partial remission (PR) or complete remission (CR) and the healthy donors) was evaluated by flow cytometry.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Flow Cytometry. Forkhead Transcription Factors / genetics. Humans. Interleukin-2 Receptor alpha Subunit / immunology. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488606.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-2 Receptor alpha Subunit
  •  go-up   go-down


25. Park HH, Kim M, Lee BH, Lim J, Kim Y, Lee EJ, Min WS, Kang CS, Kim WI, Shim SI, Han K: Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia. Ann Clin Lab Sci; 2006;36(1):7-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia.
  • The quantitative levels of intracellular cytokines IL-4, IL-10, and IFN-gamma (ie, the number of bound PE-conjugated antibody molecules/cell) of leukemic cells and bone marrow T cells (bmT cells) of acute leukemia patients were analyzed by flow cytometry.
  • The IFN-gamma level was highest in the acute promyelocytic leukemia (APL) group (495 +/- 159), and lowest in the ALL group (252 +/- 119).
  • There were no significant correlations of these cytokine levels with 2-yr survival rate, complete remission (CR) rate, or relapse rate.
  • In summary, leukemic cell and bmT cell cytoplasmic expression profiles of IL-4, IL-10, and IFN-gamma are characteristic for each diagnostic group of acute leukemia patients and the profiles of bmT cells are normal at the time of CR.
  • [MeSH-major] Bone Marrow Cells / metabolism. Interferon-gamma / blood. Interleukin-10 / blood. Interleukin-4 / blood. Leukemia / metabolism. T-Lymphocytes / metabolism
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Leukemia, Myeloid / blood. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / metabolism. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Remission Induction

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501231.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


26. Hentschel N, Krusch M, Kiener PA, Kolb HJ, Salih HR, Schmetzer HM: Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma. Eur J Haematol; 2006 Aug;77(2):91-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
  • In this study, we correlated sCD137L and sCD178 levels in sera of 42 samples of patients with acute myeloid leukemia (AML) and 46 samples of patients with non-Hodgkin's lymphoma (NHL) with stages, subtypes, and the clinical course of the diseases and determined cut-off values with maximum probability for significant differentiation between cases with higher/lower probability for progress free survival.
  • Furthermore, in AML patients sCD137L levels correlate significantly with the probabilities to achieve complete remission (CR), stay in CR or with progress of the disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Leukemia, Myeloid / blood. Lymphoma, Non-Hodgkin / blood. Membrane Glycoproteins / blood. Neoplasm Proteins / blood. Tumor Necrosis Factors / blood
  • [MeSH-minor] 4-1BB Ligand. Acute Disease. Adult. Aged. Aged, 80 and over. Blast Crisis / blood. Child, Preschool. Disease Progression. Disease-Free Survival. Fas Ligand Protein. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Lymphoma, B-Cell / blood. Lymphoma, T-Cell / blood. Male. Middle Aged. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / blood. Prognosis. Retrospective Studies. Solubility. Survival Analysis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800841.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TNFSF9 protein, human; 0 / Tumor Necrosis Factors
  •  go-up   go-down


27. Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Kim CC: Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia; 2009 Oct;23(10):1763-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
  • The aim of this prospective study was to investigate the feasibility of reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) in 37 adults with high-risk acute lymphoblastic leukemia (ALL) in first (n=30) or second (n=7) complete remission (CR).
  • The cumulative incidence of acute (grades II-IV) and chronic GVHD was 43.2 and 65.6%, respectively.
  • This study suggests that RIC-SCT is a potential therapeutic approach for adults with high-risk ALL in remission who are ineligible for myeloablative transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Feasibility Studies. Female. Graft Survival. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Male. Melphalan / administration & dosage. Middle Aged. Prospective Studies. Remission Induction. Risk Factors. Survival Rate. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440217.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


28. Chim CS, Lie AK, Liang R, Au WY, Kwong YL: Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor. Bone Marrow Transplant; 2007 Aug;40(4):339-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor.
  • We analyzed the outcome of 108 adult acute lymphoblastic leukemia patients undergoing allogeneic bone marrow transplantation (BMT).
  • Two-thirds of patients received allogeneic BMT in first complete remission (CR1) BMT.
  • Salvage BMT was performed in 21 and 16 patients at second complete remission (CR2) and beyond CR2.
  • Multivariate analyses (including age, sex, disease status, donor type, acute graft-versus-host disease (aGVHD), stem cell source, cytogenetics, grade 1/2 aGVHD and TBI-containing conditioning regimen) identified age<35, BMT at CR1 and grade 1/2 aGVHD as favorable factors for OS.
  • [MeSH-major] Bone Marrow Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Disease-Free Survival. Female. Graft vs Host Disease. Histocompatibility Testing. Hong Kong. Humans. Kaplan-Meier Estimate. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Salvage Therapy. Transplantation, Homologous


29. Liu XM, Chen YZ, Huang MJ, Liu X, Guo JR: [The potential prognostic influence of granulocyte-colony stimulating factor in acute leukemia]. Zhonghua Nei Ke Za Zhi; 2005 Jul;44(7):518-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The potential prognostic influence of granulocyte-colony stimulating factor in acute leukemia].
  • OBJECTIVE: To investigate the potential influence of granulocyte-colony stimulating factor (G-CSF) on the prognosis of patients with acute leukemia(AL).
  • METHODS: In 171 evaluable cases with AL, the complete remission (CR) rate post first course of chemotherapy, CR rate, effective rate, duration of leucopenia post chemotherapy, CR duration, lifespan and the relationship between the dosage of G-CSF and CR duration or lifespan were retrospectively analyzed with Chi-square test, paired t-test, Cox regression, Kaplan-Meier and rank correlation method.
  • For remission induction and postremission therapy, the cases with acute myeloid leukemia (AML) received chemotherapy regimes based on daunorubicin + ara-C (DA), homoharringtonine + ara-C (HA) or mitoxantrone + ara-C (MA).
  • The patients with acute lymphocyte leukemia (ALL) were treated with regimes based on vinblastine + daunorubicin + prednisone (VDP), vinblastine + adriamycin + prednisone (VAP), vinblastine + mitoxantrone + prednisone (VMP) or cyclophosphamide + vinblastine + daunorubicin + prednisone(CODP).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Leukocyte Count. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080844.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


30. Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC, Ossenkoppele G, Sonneveld P, Maertens J, van Marwijk Kooy M, Schaafsma MR, Wijermans PW, Biesma DH, Wittebol S, Voogt PJ, Baars JW, Zachée P, Verdonck LF, Löwenberg B, Dekker AW, Dutch-Belgian HOVON Cooperative Group: Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood; 2009 Feb 5;113(6):1375-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.
  • While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hematopoietic stem cell transplantation (allo-SCT) is still disputed in adult patients with standard-risk ALL.
  • We evaluated outcome of patients with ALL in first complete remission (CR1), according to a sibling donor versus no-donor comparison.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Autologous / methods. Transplantation, Homologous / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Living Donors. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Prospective Studies. Remission Induction. Risk Factors. Siblings. Transplantation Conditioning. Treatment Outcome. Young Adult


31. Okada A, Hatori M, Hosaka M, Watanuki M, Itoi E: Secondary osteosarcoma arising after treatment for childhood hematologic malignancies. Ups J Med Sci; 2009;114(4):249-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report two cases of secondary osteosarcoma arising after treatment for childhood hematologic malignancies (non-Hodgkin's lymphoma and lymphoblastic leukemia).
  • He received chemotherapy, radiation, and bone-marrow transplantation and then was in complete remission.
  • A 26-year-old man, at the age of 6, was diagnosed as having acute lymphoblastic leukemia (ALL).
  • [MeSH-minor] Adult. Alkaline Phosphatase / blood. Biomarkers, Tumor / blood. Child. Humans. Lymphoma, T-Cell / therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1972 Oct;54(7):1479-89 [4510800.001]
  • [Cites] Eur J Surg Oncol. 2009 Oct;35(10):1030-6 [19232880.001]
  • [Cites] Skeletal Radiol. 1982;8(4):279-83 [6293097.001]
  • [Cites] J Clin Pathol. 1987 Apr;40(4):398-403 [3584482.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] Tumori. 1987 Aug 31;73(4):331-6 [3477902.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):339-47 [2822073.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):193-201 [1985716.001]
  • [Cites] Oncology (Williston Park). 1991 May;5(5):135-41; discussion 142, 147-8 [1831995.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] Clin Orthop Relat Res. 1992 Jan;(274):275-81 [1729013.001]
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] Eur J Radiol. 2001 Jun;38(3):235-48 [11399379.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2074-9; discussion 2079-81 [11597387.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1959-66 [11745271.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Oct;24(7):572-4 [12368699.001]
  • [Cites] Int J Clin Oncol. 2002 Oct;7(5):318-21 [12402067.001]
  • [Cites] Bone Marrow Transplant. 2003 Mar;31(5):353-9 [12634726.001]
  • [Cites] Acta Paediatr Scand. 1991 Dec;80(12):1220-8 [1785295.001]
  • [Cites] Clin Chim Acta. 1991 Sep 14;201(1-2):27-33 [1790624.001]
  • [Cites] J Bone Joint Surg Am. 1992 Aug;74(7):1079-83 [1522094.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1224-30 [8435797.001]
  • [Cites] Ann Clin Biochem. 1993 Jul;30 ( Pt 4):355-72 [8379650.001]
  • [Cites] BMJ. 1993 Oct 23;307(6911):1030-6 [8251777.001]
  • [Cites] Oncology. 1996 Jul-Aug;53(4):275-80 [8692530.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Int J Cancer. 1998 Jul 29;77(3):370-7 [9663598.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1169-74 [16054775.001]
  • [Cites] Cancer. 1979 Jun;43(6):2178-81 [287547.001]
  • (PMID = 19961270.001).
  • [ISSN] 2000-1967
  • [Journal-full-title] Upsala journal of medical sciences
  • [ISO-abbreviation] Ups. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.1 / Alkaline Phosphatase
  • [Other-IDs] NLM/ PMC2852780
  •  go-up   go-down


32. Abdallah E, Hajji Z, Mellal Z, Belmekki M, Bencherifa F, Berraho A: [Macular serous detachment revealing acute lymphoblastic leukemia]. J Fr Ophtalmol; 2005 Jan;28(1):39-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Macular serous detachment revealing acute lymphoblastic leukemia].
  • The investigations showed the diagnosis of acute lymphoblastic leukemia.
  • Steroids and chemotherapy led to complete remission with normal visual acuity during a follow-up of 29 months.
  • DISCUSSION: Ocular involvement is seen in 28%-80% of leukemia cases.
  • CONCLUSION: Ocular manifestations of leukemia are frequent but rarely reveal the disease.
  • However, the diagnosis of leukemia should be considered in case of pigmentary epithelium involvement.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retinal Detachment / etiology
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767897.001).
  • [ISSN] 0181-5512
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


33. Tobinai K, Takeyama K, Arima F, Aikawa K, Kobayashi T, Hanada S, Kasai M, Ogura M, Sueoka E, Mukai K, Tajima K, Fukuda H, Shirakawa S, Hotta T, Masanori S, Lymphoma Study Group of the Japan Clinical Oncology Group: Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004. Cancer Sci; 2007 Sep;98(9):1350-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004.
  • Granulocyte colony-stimulating factor (G-CSF)-supported, post-remission chemotherapy (Cx) for adult acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) was evaluated.
  • For patients achieving complete response (CR), two courses of post-remission Cx (course A of daunorubicin, cytosine arabinoside, vindesine, PSL plus IT-MTX; course B of mitoxantrone, etoposide, vincristine, PSL plus IT-MTX) with the use of G-CSF were repeated alternately; thereafter, maintenance Cx including MTX and 6-mercaptopurine was given for 2 years.
  • Among the 119 patients achieving CR, five died in remission, 76 relapsed, and the remaining 38 were alive without disease.
  • In conclusion, G-CSF-supported, intensive post-remission Cx and subsequent SCT are worthy of further investigation for the treatment of adult ALL and LBL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640299.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


34. Vakiani E, Savage DG, Pile-Spellman E, El-Tamer M, Singh IR, Murty VS, Alobeid B, Bhagat G: T-Cell lymphoblastic lymphoma presenting as bilateral multinodular breast masses: a case report and review of the literature. Am J Hematol; 2005 Nov;80(3):216-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-Cell lymphoblastic lymphoma presenting as bilateral multinodular breast masses: a case report and review of the literature.
  • We report on a 41-year-old woman with T-cell lymphoblastic lymphoma who presented with multiple bilateral breast masses.
  • She remains in complete remission 24 months after diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Cranial Irradiation. Diagnosis, Differential. Female. Humans. Radiotherapy, Adjuvant. Remission Induction / methods

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247747.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA149719
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Bonate PL, Arthaud L, Cantrell WR Jr, Stephenson K, Secrist JA 3rd, Weitman S: Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov; 2006 Oct;5(10):855-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment of acute leukaemias, which are the most common paediatric cancers, has improved considerably in recent decades, with complete response rates approaching approximately 90% in some cases.
  • However, there remains a major need for treatments for patients who do not achieve or maintain complete remission, for whom the prognosis is very poor.
  • In this article, we describe the challenges involved in the discovery and development of clofarabine, a second-generation nucleoside analogue that received accelerated approval from the US FDA at the end of 2004 for the treatment of paediatric patients 1-21 years old with relapsed or refractory acute lymphoblastic leukaemia after at least two prior regimens.
  • It is the first such drug to be approved for paediatric leukaemia in more than a decade, and the first to receive approval for paediatric use before adult use.
  • [MeSH-minor] Clinical Trials as Topic. Drug Approval. Humans. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17016426.001).
  • [ISSN] 1474-1776
  • [Journal-full-title] Nature reviews. Drug discovery
  • [ISO-abbreviation] Nat Rev Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  • [Number-of-references] 60
  •  go-up   go-down


36. Choi J, Foss F: Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia. Yale J Biol Med; 2006 Dec;79(3-4):169-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
  • Refractory T-lymphoblastic leukemia in adults has a poor prognosis in patients who relapse after allogeneic stem cell transplantation, and relatively few new agents have demonstrated activity.
  • We used low dose clofarabine and induced a remission in a patient who relapsed in the skin and marrow after allogeneic transplant and was refractory to nelarabine and report a near complete response, suggesting significant activity for low intermittent dose clofarabine in patients with relapsed T-cell leukemias.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Adult. Bone Marrow Neoplasms / drug therapy. Bone Marrow Neoplasms / secondary. Clinical Trials as Topic. Drug Administration Schedule. Drug Resistance, Neoplasm. Humans. Immunophenotyping. Male. Recurrence. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary. Stem Cell Transplantation. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):855-63 [17016426.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3396-403 [15908652.001]
  • [Cites] Mol Pharmacol. 2006 Jan;69(1):346-53 [16234483.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1917-23 [16622268.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2386-94 [1707752.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1167-73 [12637486.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • (PMID = 17940627.001).
  • [ISSN] 1551-4056
  • [Journal-full-title] The Yale journal of biology and medicine
  • [ISO-abbreviation] Yale J Biol Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 60158CV180 / nelarabine; 762RDY0Y2H / clofarabine
  • [Other-IDs] NLM/ PMC1994805
  •  go-up   go-down


37. Lee S, Kim YJ, Chung NG, Lim J, Lee DG, Kim HJ, Min CK, Lee JW, Min WS, Kim CC: The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer; 2009 Feb 1;115(3):561-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • BACKGROUND: Previously, the authors demonstrated the positive impact of imatinib on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL).
  • RESULTS: After the first 4-week imatinib therapy, 11 patients (21.2%) achieved molecular remission, and the remaining 41 patients had a reduction in BCR-ABL transcript levels (median, 3.21 log) from baseline value.
  • Forty-eight (92.3%) of the 52 patients received stem cell transplantation during first complete remission.
  • [MeSH-major] Neoplasm, Residual / diagnosis. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Benzamides. Disease-Free Survival. Female. Follow-Up Studies. Humans. Imatinib Mesylate. Male. Middle Aged. Prognosis. Recurrence. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19117346.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


38. Abou Mourad YR, Fernandez HF, Kharfan-Dabaja MA: Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Biol Blood Marrow Transplant; 2008 Sep;14(9):949-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors.
  • Allogeneic hematopoietic cell transplantation in first complete remission (CR1) is considered the standard of care, and the only established therapy that offers a possibility of cure for patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
  • Incorporating imatinib during the induction/consolidation phase is facilitating a higher number of potentially curative allografts by improving both remission rates and/or the durability of responses in patients with Ph+ ALL.
  • [MeSH-major] Algorithms. Hematopoietic Stem Cell Transplantation. Philadelphia Chromosome. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Benzamides. Disease-Free Survival. Glucocorticoids / therapeutic use. Humans. Imatinib Mesylate. Recurrence. Remission Induction. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721758.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Glucocorticoids; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 57
  •  go-up   go-down


39. Patel B, Rai L, Buck G, Richards SM, Mortuza Y, Mitchell W, Gerrard G, Moorman AV, Duke V, Hoffbrand AV, Fielding AK, Goldstone AH, Foroni L: Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol; 2010 Jan;148(1):80-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.
  • The predictive value of molecular minimal residual disease (MRD) monitoring using polymerase chain reaction amplification of clone-specific immunoglobulin or T-cell Receptor rearrangements was analysed in 161 patients with non T-lineage Philadelphia-negative acute lymphoblastic leukaemia (ALL) participating in the UK arm of the international ALL trial UKALL XII/Eastern Cooperative Oncology Group (ECOG) 2993.
  • MRD status best discriminated outcome after phase 2 induction, when the relative risk of relapse was 8.95 (2.85-28.09)-fold higher in MRD-positive (> or =10(-4)) patients and the 5-year RFS 15% [95% confidence interval (CI) 0-40%] compared to 71% (56-85%) in MRD-negative (<10(-4)) patients (P = 0.0002) When MRD was detected prior to autologous stem cell transplantation (SCT), a significantly higher rate of treatment failure was observed [5-year RFS 25% (CI 0-55%) vs. 77% (95% CI 54-100%) in MRD-negative/<10(-4), P = 0.01] whereas in recipients of allogeneic-SCT in first complete remission, MRD positivity pre-transplant did not adversely affect outcome.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Epidemiologic Methods. Hematopoietic Stem Cell Transplantation. Humans. Immunophenotyping. Middle Aged. Neoplasm, Residual. Prognosis. Recurrence. Treatment Failure. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863538.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


40. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL Jr: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant; 2006 Jan;12(1):1-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review.
  • Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute lymphoblastic leukemia in adults (> or =15 years) is presented and critically evaluated in this systematic evidence-based review.
  • Treatment recommendations based on the evidence are presented and were reached unanimously by a panel of acute lymphoblastic leukemia experts.
  • The priority areas of needed future research for adult acute lymphoblastic leukemia are: definition of patients at high risk in first complete remission, beyond Philadelphia chromosome positive; outcomes of SCT in older (>50 years) adults; determination if reduced intensity versus myeloablative conditioning regimens yield an equivalent graft-versus-leukemia effect with reduced toxicity; monitoring of minimal residual disease to achieve disease control before SCT; and the use of cord blood and other alternative sources of stem cells for use in adult SCT recipients.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399566.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 83
  •  go-up   go-down


41. Roberson JR, Spraker HL, Shelso J, Zhou Y, Inaba H, Metzger ML, Rubnitz JE, Ribeiro RC, Sandlund JT, Jeha S, Pui CH, Howard SC: Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. Leukemia; 2009 Feb;23(2):245-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia.
  • Hyperglycemia adversely affects outcome in adult patients with acute lymphoblastic leukemia (ALL), but its impact on children with this disease is unknown.
  • We evaluated the relationship between hyperglycemia during remission induction therapy and clinical outcomes among pediatric patients with ALL.
  • We reviewed the records of patients enrolled on four consecutive ALL protocols (Total Therapy protocols XIIIA, XIIIB, XIV and XV) at St Jude Children's Research Hospital from 1991 to 2007 and identified those who experienced hyperglycemia (glucose >or=200 mg per 100 ml) during remission induction.
  • Complete remission (CR) rates at the end of induction, event-free survival (EFS), overall survival (OS), cumulative incidence of relapse and occurrence of infections were compared between those who did and did not experience hyperglycemia.
  • Of 871 patients analyzed, 141 (16%) experienced hyperglycemia during remission induction.
  • Pediatric patients with or without hyperglycemia during remission induction for ALL have similar clinical outcome.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pract. 2004 Mar-Apr;10 Suppl 2:46-52 [15251640.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1677-84 [15378506.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Pediatrics. 1972 Apr;49(4):590-5 [4501679.001]
  • [Cites] Cancer Res. 1973 Jan;33(1):1-4 [4565907.001]
  • [Cites] Diabetes. 1974 Jan;23(1):9-15 [4809622.001]
  • [Cites] Diabetologia. 1978 Aug;15(2):113-6 [359390.001]
  • [Cites] Diabetes. 1980 Jul;29(7):528-31 [6991339.001]
  • [Cites] Metabolism. 1980 Dec;29(12):1262-6 [7005618.001]
  • [Cites] J Pediatr. 1981 Jul;99(1):46-50 [6454771.001]
  • [Cites] Horm Metab Res. 1984 Dec;16 Suppl 1:92-6 [6398268.001]
  • [Cites] J Trauma. 1990 Jul;30(7):830-2; discussion 832-3 [2380999.001]
  • [Cites] Indian J Cancer. 1993 Jun;30(2):72-6 [8225380.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1993 Jun;51(6):457-61 [8281494.001]
  • [Cites] FEMS Immunol Med Microbiol. 1993 Dec;7(4):315-20 [8136782.001]
  • [Cites] Arch Dis Child. 1996 Feb;74(2):101-7 [8660070.001]
  • [Cites] Horm Metab Res. 1996 Jun;28(6):267-70 [8811326.001]
  • [Cites] J Appl Physiol (1985). 1997 Nov;83(5):1566-74 [9375321.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] J Pediatr. 2005 Jan;146(1):30-4 [15644818.001]
  • [Cites] Leukemia. 2005 Apr;19(4):537-44 [15690069.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):960-3 [15700246.001]
  • [Cites] Acta Paediatr. 2006 Apr;95(4):486-93 [16720499.001]
  • [Cites] Pediatrics. 2006 Jul;118(1):173-9 [16818563.001]
  • [Cites] Pediatr Crit Care Med. 2006 Jul;7(4):351-5 [16738506.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):259-63 [17635005.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1207-12 [18266226.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1932-9 [18421047.001]
  • [Cites] Helv Paediatr Acta. 1973 Oct;28(4):365-9 [4519479.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Trauma. 2001 Sep;51(3):540-4 [11535907.001]
  • [Cites] J Biol Chem. 2001 Oct 12;276(41):37747-53 [11489902.001]
  • [Cites] N Engl J Med. 2001 Nov 8;345(19):1359-67 [11794168.001]
  • [Cites] Pancreas. 2002 Jan;24(1):26-33 [11741179.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):978-82 [11889147.001]
  • [Cites] Childs Nerv Syst. 2002 Apr;18(3-4):129-36 [11981619.001]
  • [Cites] Blood Rev. 2002 Dec;16(4):225-43 [12350366.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3084-91 [12915598.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2041-7 [14559958.001]
  • [Cites] J Trauma. 2003 Dec;55(6):1035-8 [14676647.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1179-85 [15022284.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] J Pediatr Surg. 2004 Jun;39(6):898-901; discussion 898-901 [15185221.001]
  • [Cites] Pediatr Crit Care Med. 2004 Jul;5(4):329-36 [15215001.001]
  • (PMID = 18923438.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / U01 GM061393-09; United States / NCI NIH HHS / CA / CA-78224; United States / NCI NIH HHS / CA / R01 CA078224-09; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / CA-60419; United States / NCI NIH HHS / CA / R37 CA036401-21; United States / NCI NIH HHS / CA / R01 CA060419-13; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; None / None / / R01 CA051001-15; United States / NCI NIH HHS / CA / CA-36401; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / R01 CA051001-15; United States / NCI NIH HHS / CA / P30 CA021765; None / None / / R01 CA078224-09; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA036401; None / None / / R01 CA060419-13; United States / NCI NIH HHS / CA / P30 CA021765-30; United States / NIGMS NIH HHS / GM / GM-61393; United States / NCI NIH HHS / CA / U01 CA060419; United States / NCI NIH HHS / CA / CA036401-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS104861; NLM/ PMC2706830
  •  go-up   go-down


42. Sung WJ, Kim DH, Sohn SK, Kim JG, Baek JH, Jeon SB, Moon JH, Ahn BM, Lee KB: Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia. Jpn J Clin Oncol; 2005 Oct;35(10):612-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
  • OBJECTIVE: The current trial attempted to evaluate the efficacy and toxicity of a salvage therapy consisting of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide for acute leukemia patients in refractory or relapsed states.
  • METHODS: A total of 51 patients with refractory or relapsed acute leukemia were included in the current trial.
  • Twenty-nine patients with acute myeloid leukemia (AML) received a salvage therapy of amsacrine plus IDAC and etoposide, while 22 patients with acute lymphoblastic leukemia (ALL) received amsacrine plus IDAC.
  • RESULTS: The overall complete remission rate was 55% (45% for AML, 68% for ALL) and the median duration of overall survival was 144 days (95% confidence interval = 101-186 days).
  • CONCLUSION: A salvage therapy consisting of amsacrine plus IDAC with or without etoposide appears to be safe and an effective bridge therapy into a stem cell transplantation programme for patients with refractory or relapsed acute leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Amsacrine / administration & dosage. Cytarabine / administration & dosage. Diarrhea / chemically induced. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Nausea / chemically induced. Remission Induction. Survival Rate. Treatment Outcome. Vomiting, Anticipatory / etiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172175.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


43. Hato A, Murayama T, Nishikawa S, Kajimoto K, Gomyo H, Sugimoto T, Mizuno I, Koizumi T: Philadelphia chromosome positive acute lymphoblastic leukemia showing normal karyotype in G-banding chromosomal examination before chemotherapy. Hematology; 2005 Oct;10(5):379-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Philadelphia chromosome positive acute lymphoblastic leukemia showing normal karyotype in G-banding chromosomal examination before chemotherapy.
  • A diagnosis of acute lymphoblastic leukaemia was made on the basis of a 61.6% infiltration of leukemic cells in his bone marrow.
  • He received combination chemotherapy, and achieved hematological complete remission.
  • [MeSH-major] Bone Marrow / pathology. Leukemic Infiltration / pathology. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Chromosome Banding. Humans. In Situ Hybridization, Fluorescence / methods. Karyotyping. Male. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273725.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Jabbour EJ, Faderl S, Kantarjian HM: Adult acute lymphoblastic leukemia. Mayo Clin Proc; 2005 Nov;80(11):1517-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia.
  • Much progress has been made in understanding the biology of and therapy for acute lymphoblastic leukemia (ALL).
  • Adaptation of successful treatment strategies in children with ALL has resulted in similar complete remission rates in adults.
  • Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics is vital to the therapeutic success in adult ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Humans. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16295033.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


45. Malhotra P, Varma S, Varma N, Kumari S, Das R, Jain S, Ahluwalia J, Mahi S, Sharma SC, Radhika S: Outcome of adult acute lymphoblastic leukemia with BFM protocol in a resource-constrained setting. Leuk Lymphoma; 2007 Jun;48(6):1173-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of adult acute lymphoblastic leukemia with BFM protocol in a resource-constrained setting.
  • Cure rates for adult acute lymphoblastic leukemia (ALL) in developing countries are significantly lower because of problems unique to these countries.
  • We assessed some of the problems in adult ALL patients (>12 years of age) in a tertiary care hospital of northwest India with modified BFM regimen.
  • Complete remission (CR) was achieved in 85.6% patients after induction therapy and 40% patient relapsed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Asparaginase / adverse effects. Asparaginase / therapeutic use. Child. Combined Modality Therapy. Daunorubicin / adverse effects. Daunorubicin / therapeutic use. Female. Health Resources / economics. Health Resources / supply & distribution. Humans. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Recurrence. Remission Induction. Survival Analysis. Treatment Outcome. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577781.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


46. Larson RA: Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant; 2009 Jan;15(1 Suppl):11-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission.
  • Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, and outcomes vary by patient age, immunophenotype, and clinical, cytogenetic, and molecular features.
  • Available data indicate no clear consensus as to whether there is an advantage to allogeneic HCT over chemotherapy for adults with ALL with standard-risk features while in the first complete remission (CR1).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Age Factors. Humans. Remission Induction. Risk. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147070.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-14599; United States / NCI NIH HHS / CA / CA-31946
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


47. Lee JH, Choi SJ, Lee JH, Seol M, Lee YS, Ryu SG, Park CJ, Chi HS, Lee MS, Yun S, Lee JS, Lee KH: Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia. Haematologica; 2005 Oct;90(10):1380-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia.
  • BACKGROUND AND OBJECTIVES: Several reports have suggested that the graft-versus-leukemia effect at extramedullary (EM) sites might be less prominent than that in the bone marrow (BM).
  • We analyzed the effect of graft-versus-host disease (GVHD) on BM and EM relapses in 194 consecutive patients with acute leukemia who underwent allogeneic hematopoietic cell transplantation at a single institute.
  • Patients who developed acute GVHD after transplantation had significantly higher relapse-free survival (69.2% vs. 52.4%; p=0.042) and BM RFS (80.7% vs. 59.1%; p=0.030) compared to those who did not.
  • However, EM RFS was similar between patients with and without acute GVHD (76.7% vs. 78.2%; p=0.744).
  • Among the 65 patients who relapsed, 32 patients attained complete remission with salvage treatments and 22 experienced a second relapse, which occurred in the BM (n=9), BM and EM sites (n=1), or EM sites (n=12).
  • [MeSH-major] Bone Marrow / pathology. Graft vs Host Disease / diagnosis. Graft vs Leukemia Effect / immunology. Leukemia, Myeloid, Acute / surgery. Neoplasm Recurrence, Local / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Male. Middle Aged. Multivariate Analysis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Oct;90(10):1301B [16219559.001]
  • [CommentIn] Haematologica. 2006 Mar;91(3):ELT03 [16533736.001]
  • (PMID = 16219575.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


48. Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp TR, Lazarus HM, Lewis VA, McCarthy P, Rizzieri DA, Sabloff M, Szer J, Tallman MS, Weisdorf DJ: The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood; 2010 Jul 22;116(3):366-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.
  • We examined the efficacy of reduced-intensity conditioning (RIC) and compared outcomes of 93 patients older than 16 years after RIC with 1428 patients receiving full-intensity conditioning for allografts using sibling and unrelated donors for Philadelphia-negative acute lymphoblastic leukemia (ALL) in first or second complete remission.
  • The RIC versus full-intensity conditioning groups had slightly, but not significantly, less acute grade II-IV graft-versus-host disease (39% vs 46%) and chronic graft-versus-host disease (34% vs 42%), yet similar transplantation-related mortality.
  • Multivariate analysis demonstrated significantly improved overall survival with: Karnofsky performance status more than 80, first complete remission, lower white blood count, well-matched unrelated or sibling donors, transplantation since 2001, age younger than 30 years, and conditioning with TBI, but no independent impact of conditioning intensity.
  • RIC merits further investigation in prospective trials of adult ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Oct 1;96(7):2419-25 [11001893.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33 [19896087.001]
  • [Cites] N Engl J Med. 1979 May 10;300(19):1068-73 [34792.001]
  • [Cites] Blood. 1989 May 1;73(6):1720-8 [2653460.001]
  • [Cites] Bone Marrow Transplant. 1998 Jan;21(2):153-8 [9489632.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(6):549-56 [15756282.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):683-9 [16113673.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Bone Marrow Transplant. 2006 Oct;38(7):467-75 [16892073.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Haematologica. 2008 Feb;93(2):303-6 [18245655.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Bone Marrow Transplant. 2008 Apr;41(7):635-42 [18084335.001]
  • [Cites] Blood. 2008 Jul 15;112(2):426-34 [18398065.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Mar;15(3):367-9 [19203728.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2902-5 [19179301.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3634-41 [19581540.001]
  • [Cites] Haematologica. 2009 Oct;94(10):1399-406 [19648167.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Nov;15(11):1407-14 [19822300.001]
  • [Cites] Haematologica. 2003 May;88(5):555-60 [12745275.001]
  • (PMID = 20404137.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / HHSH234200637015C; United States / NCI NIH HHS / CA / U24-CA76518; United States / NHLBI NIH HHS / HL / U01 HL069294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] G1LN9045DK / Busulfan; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC2913452
  •  go-up   go-down


49. He GS, Zhang XH, Yao L, Zhang R, Chen ZX, Wu DP, Sun AN, Jin ZM, Qiu HY, Hu XH: [Acute T cells lymphoblastic leukemia with a t(1;19)(q23;p13) and E2A-PBX1 in an adult: one case report and literature review]. Zhonghua Xue Ye Xue Za Zhi; 2009 Oct;30(10):675-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute T cells lymphoblastic leukemia with a t(1;19)(q23;p13) and E2A-PBX1 in an adult: one case report and literature review].
  • OBJECTIVE: To report a case of T cell acute lymphoblastic leukemia (ALL) with t(1;19)(q23;pl3) and E2A-PBX1 fusion gene, which is a characteristic translocation of childhood B cell ALL (B-ALL).
  • The patient was induced with hyper CVAD regimen (cyclophosphamide, vincristine, adriamycin, and dexamethasone), and achieved complete remission with normal cytogenetic karyotype 46 XY[10], and negative E2A-PBX1.
  • CONCLUSION: t(1;19)E2A-PBX1(+) can be implicated in adult T-ALL, besides childhood B-ALL.
  • [MeSH-major] Homeodomain Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Humans. Karyotyping. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954663.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 146150-85-8 / E2A-Pbx1 fusion protein
  •  go-up   go-down


50. Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández-Rivas JM, Moreno MJ, del Potro E, Torm M, Rivas C, Besalduch J, Sanz MA, Ortega JJ, PETHEMA Group, Spain: Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica; 2005 Oct;90(10):1346-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
  • BACKGROUND AND OBJECTIVES: The optimal post-remission therapy for adults with high-risk acute lymphoblastic leukemia (ALL) is not well established.
  • This multicenter randomized trial by the Spanish PETHEMA Group was addressed to compare three options of post-remission therapy in adults with high-risk ALL: chemotherapy, allogeneic stem cell transplantation (SCT) and autologous SCT.
  • Patients in complete remission with an HLA-identical family donor were assigned to allogeneic SCT (n=84) and the remaining were randomized to autologous SCT (n=50) or to delayed intensification followed by maintenance chemotherapy up to 2 years in complete remission (n=48).
  • RESULTS: Overall, 183 patients achieved complete remission (82%).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Oct;90(10):1299 [16219555.001]
  • (PMID = 16219571.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


51. Zohren F, Czibere A, Bruns I, Fenk R, Schroeder T, Gräf T, Haas R, Kobbe G: Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia. Bone Marrow Transplant; 2009 Dec;44(12):785-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
  • In this prospective study, we examined the toxicity and efficacy of an intensified conditioning regimen for treatment of patients with relapsed or high-risk acute lymphoblastic leukemia who undergo allogeneic hematopoietic stem cell transplantation.
  • At the time of hematopoietic stem cell transplantation, 10 patients were in complete remission (8 CR1; 2 CR2), 3 with primary refractory and 2 suffered from refractory relapse.
  • All patients achieved a complete remission after hematopoietic stem cell transplantation; and after a median follow-up time of 1091 days (range, 334-1554 days), nine patients (60%) are alive and free from disease, including three patients with prior refractory disease.
  • Thus, conditioning with the FLAMSA-ATG-TBI regimen is a feasible and effective alternative for patients with relapsed or high-risk acute lymphoblastic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Amsacrine / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Recurrence. Risk Factors. Survival Rate. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Whole-Body Irradiation / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19430496.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


52. Kim AS, Goldstein SC, Luger S, Van Deerlin VM, Bagg A: Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: a nonrandom event associated with imatinib? Am J Clin Pathol; 2008 Apr;129(4):639-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: a nonrandom event associated with imatinib?
  • Imatinib has dramatically altered the natural history of chronic myelogenous leukemia (CML), with the majority of patients now experiencing long-term remission and improved survival.
  • We report 2 cases of sudden BCR/ABL1+ blast crisis in patients with CML who had achieved complete hematologic remission with imatinib therapy but were obligated to discontinue therapy owing to pancytopenia.
  • These sudden blast crises were unusual at 3 levels: first, they were of precursor T lymphoblastic lineage; second, they had a primary extranodal presentation without overt bone marrow involvement; and third, they developed after recent cessation of imatinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Blast Crisis / pathology. Leukemia, Myeloid, Chronic-Phase / pathology. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Biomarkers, Tumor / analysis. Bone Marrow / chemistry. Bone Marrow / pathology. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. Imatinib Mesylate. Immunophenotyping. In Situ Hybridization, Fluorescence. Lymph Nodes / chemistry. Lymph Nodes / pathology. Male. RNA, Neoplasm / analysis. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343792.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Neoplasm; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


53. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM, Goldstone AH, Medical Research Council of the United Kingdom Adult ALL Working Party, Eastern Cooperative Oncology Group: Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood; 2007 Feb 01;109(3):944-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
  • Most adults with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR) will relapse.
  • Factors predicting a good outcome after salvage therapy were young age (OS of 12% in patients younger than 20 years vs OS of 3% in patients older than 50 years; 2P<.001) and short duration of first remission (CR1) (OS of 11% in those with a CR1 of more than 2 years versus OS of 5% in those with a CR1 of less than 2 years; 2P<.001).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Risk Factors. Salvage Therapy. Survival Rate. Time Factors. Treatment Outcome


54. Lin DJ, Fan RF, Liu XF: [Significance of DNA methylation status of runx3 gene promoter region in acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr;16(2):263-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of DNA methylation status of runx3 gene promoter region in acute leukemia].
  • This study was aimed to investigate the effects of methylation of runx3 gene promoter on pathogenesis of acute leukemia (AL) and its clinical significance.
  • Patients without methylation of runx3 gene had a lower percentage of blasts in bone marrow and a higher complete remission rate of first chemotherapy than those with methylation of runx3 gene.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18426645.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 3 Subunit; 0 / RNA, Messenger; 0 / Runx3 protein, human
  •  go-up   go-down


55. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J, Children's Cancer Group, Cancer and Leukemia Group B studies: What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood; 2008 Sep 1;112(5):1646-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
  • We performed a retrospective comparison of presenting features, planned treatment, complete remission (CR) rate, and outcome of 321 adolescents and young adults (AYAs) ages 16 to 20 years with newly diagnosed acute lymphoblastic leukemia (ALL) who were treated on consecutive trials in either the Children's Cancer Group (CCG) or the Cancer and Leukemia Group B (CALGB) from 1988 to 2001.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2222-30 [9196134.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1556-64 [9716583.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2032-5 [15483674.001]
  • [Cites] Eur J Haematol. 2005 Jun;74(6):466-80 [15876250.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):166-73 [16029445.001]
  • [Cites] Dan Med Bull. 2006 Feb;53(1):76-9 [16761337.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1551-61 [16955505.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:128-32 [17124051.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):254-61 [16421910.001]
  • [Cites] Blood. 2007 May 15;109(10):4164-7 [17264295.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):760-1 [12610169.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1471-80 [12627512.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] Leukemia. 1998 Feb;12(2):144-9 [9519775.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):37-51 [14766125.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S127-8 [15124704.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):273-9 [2355886.001]
  • [Cites] Cancer. 1991 Aug 15;68(4):751-8 [1855175.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [CommentIn] Blood. 2009 Feb 19;113(8):1861; author reply 1862 [19228933.001]
  • (PMID = 18502832.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA 31946; United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2518876
  •  go-up   go-down


56. Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H, Fukuda T, Ozawa Y, Kobayashi N, Kasai M, Mori T, Iwato K, Yoshida T, Onizuka M, Kawa K, Morishima Y, Suzuki R, Atsuta Y, Miyamura K: Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood; 2010 Nov 18;116(20):4368-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission.
  • To identify factors to improve the outcomes of related and unrelated allogeneic stem cell transplantations (allo-SCT) for Philadelphia chromosome-negative acute lymphocytic leukemia (Ph(-) ALL) in the first complete remission (CR1), we retrospectively analyzed 1139 Ph(-) ALL patients using the registry data, particularly the details of 641 patients transplanted in CR1.
  • After a close consideration of these factors, the outcome of allo-SCT for adult Ph(-) ALL in CR1 could be improved.
  • [MeSH-major] Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Humans. Middle Aged. Multivariate Analysis. Recurrence. Remission Induction. Risk Factors. Survival Rate. Tissue Donors. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664060.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, Balduzzi A, Owoc-Lempach J, Fagioli F, Or R, Peters C, Aversa F, Polge E, Dini G, Rocha V, Pediatric Diseases and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT): Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood; 2010 Apr 29;115(17):3437-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group.
  • T cell-depleted haploidentical hematopoietic stem cell transplantation (haploHSCT) is an option to treat children with very high-risk acute lymphoblastic leukemia (ALL) lacking an HLA-identical donor.
  • We analyzed 127 children with ALL who underwent haploHSCT in first (n = 22), second (n = 48), or third (n = 32), complete remission or in relapse (n = 25).
  • The 5-year leukemia-free survival (LFS) was 30%, 34%, 22%, and 0%, respectively.
  • A risk-factor analysis was performed for patients who underwent transplantation in remission (n = 102).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hospitals, Pediatric. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Europe. Female. Humans. Infant. Male. Remission Induction. Risk Factors. Survival Rate. Transplantation, Homologous


58. Garg R, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D, Pierce S, O'Brien S: Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer; 2009 May 15;115(10):2147-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
  • BACKGROUND: Among the well described cytogenetic abnormalities in adults with acute lymphoblastic leukemia (ALL), a translocation involving chromosomes 1 and 19 (t[1;19] [q23;p13]) occurs in a small subset but has been associated variously with an intermediate prognosis or a bad prognosis in different studies.
  • The study endpoints included the complete remission (CR) rate, the complete response duration (CRD), and overall survival (OS).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Cytarabine / administration & dosage. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Humans. Middle Aged. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Oncogene. 1999 Sep 2;18(35):4920-9 [10490826.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2155-61 [17039234.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1561-4 [18024406.001]
  • [Cites] Blood. 1986 Feb;67(2):415-20 [3455828.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2276-85 [11187919.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):484-7 [12580965.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Blood. 1984 Mar;63(3):721-4 [6607758.001]
  • [Cites] Blood. 1987 Oct;70(4):948-53 [3307953.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):994-1004 [2189958.001]
  • [Cites] Blood. 1990 Jul 1;76(1):117-22 [2364165.001]
  • [Cites] Leukemia. 1992 May;6(5):363-9 [1593901.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2601-6 [7989935.001]
  • [Cites] Leukemia. 1995 Dec;9(12):1985-9 [8609706.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1211-24 [8608207.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4252-8 [8943861.001]
  • [Cites] Curr Top Microbiol Immunol. 1997;220:25-43 [9103673.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):527-35 [9469337.001]
  • [Cites] Cancer Causes Control. 1999 Feb;10(1):35-42 [10334640.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Blood. 2006 Jul 15;108(2):465-72 [16556888.001]
  • (PMID = 19298009.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; CVAD protocol
  • [Other-IDs] NLM/ NIHMS629437; NLM/ PMC4199455
  •  go-up   go-down


59. Brassesco MS, Montaldi AP, Gras DE, Camparoto ML, Martinez-Rossi NM, Scrideli CA, Tone LG, Sakamoto-Hojo ET: Cytogenetic and molecular analysis of MLL rearrangements in acute lymphoblastic leukaemia survivors. Mutagenesis; 2009 Mar;24(2):153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and molecular analysis of MLL rearrangements in acute lymphoblastic leukaemia survivors.
  • The successful treatment of paediatric malignancies by multimodal therapy has improved outcomes for children with cancer, especially those with acute lymphoblastic leukaemia (ALL).
  • Depending on dosage, 2-12% of patients treated with topoisomerase II inhibitors and/or alkylating agents develop treatment-related acute myeloid leukaemia characterized by translocations at 11q23.
  • Even though the biological significance of these rearrangements needs further investigation, they demonstrate a degree of genome instability, indicating the relevance of cytogenetic and molecular studies during the follow-up of patients in complete clinical remission.
  • [MeSH-major] Cytogenetic Analysis. Gene Rearrangement. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Survivors
  • [MeSH-minor] Adolescent. Adult. Base Sequence. Case-Control Studies. Child. Child, Preschool. Chromosomes, Human, Pair 11 / genetics. Etoposide / therapeutic use. Humans. Molecular Sequence Data. Polymerase Chain Reaction. Teniposide / therapeutic use. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028982.001).
  • [ISSN] 1464-3804
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 6PLQ3CP4P3 / Etoposide; 957E6438QA / Teniposide
  •  go-up   go-down


60. Cimino G, Pane F, Elia L, Finolezzi E, Fazi P, Annino L, Meloni G, Mancini M, Tedeschi A, Di Raimondo F, Specchia G, Fioritoni G, Leoni P, Cuneo A, Mecucci C, Saglio G, Mandelli F, Foà R, GIMEMA Leukemia Working Party: The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. Haematologica; 2006 Mar;91(3):377-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial.
  • To verify the potential clinical and prognostic value of BCR/ABL isoforms, we analyzed 101 consecutive adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia enrolled in the GIMEMA 0496 trial between October 1996 and December 1999.
  • A complete remission was achieved in 62/92 (67.4%) patients, while 16/92 (17.4%) were resistant and 14/92 (15.2%) died of therapy-related complications.
  • Fifty-two patients underwent intensive re-induction treatment, which was followed by stem cell transplant consolidation in the 36 in persistent complete remission (allogeneic = 20 patients; autologous = 16 patients).
  • [MeSH-major] Fusion Proteins, bcr-abl / physiology. Multicenter Studies as Topic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Randomized Controlled Trials as Topic
  • [MeSH-minor] Adult. Follow-Up Studies. Genetic Markers / genetics. Genetic Markers / physiology. Humans. Multivariate Analysis. Proportional Hazards Models. Protein Isoforms / genetics. Protein Isoforms / physiology. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531262.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Protein Isoforms; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


61. Fouillard L, Labopin M, Gratwohl A, Gluckman E, Frassoni F, Beelen DW, Willemze R, Montserrat E, Blaise D, Atienza AI, Sierra J, Santos M, Gorin NC, Rocha V, Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation: Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. Haematologica; 2008 Jun;93(6):834-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
  • BACKGROUND: The possibility of performing syngeneic hematopoietic stem cell transplantation is rare and there are concerns about the absence of a graft-versus-leukemia effect following such a strategy.
  • We report the outcomes of a large series of adult patients who underwent syngeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia or acute lymphoblastic leukemia.
  • DESIGN AND METHODS: The outcomes of all syngeneic transplants for acute myeloblastic or lymphoblastic leukemia reported to the European Group for Blood and Marrow Transplantation registry were analyzed; a study of prognostic factors was performed for those transplanted in first complete remission.
  • RESULTS: One hundred and sixty-two patients, 109 with acute myeloblastic leukemia and 53 with acute lymphoblastic leukemia, were identified; 116 were in first complete remission.
  • Nineteen patients developed acute graft-versus-host disease and only three patients developed chronic graft-versus-host disease.
  • At 5 years the non-relapse mortality was 8 +/- 5%, the relapse incidence 49 +/- 8% and the leukemia-free survival 43 +/- 3%.
  • The corresponding figures for patients in first complete remission were 7 +/- 2%, 40 +/- 4% and 53 +/- 5% at 5 years.
  • Analysis of patients in first complete remission showed that the number of courses of chemotherapy required to induce first complete remission was the main risk factor: the leukemia-free survival at 5 years was 66 +/- 6% when first complete remission was reached after one induction course of chemotherapy and was only 20 +/- 9% when first complete remission was reached after at least two induction courses of chemotherapy (p = 0.0001); the relapse incidence was 30 +/- 6% and 54 +/- 10%, respectively (p = 0.007).
  • CONCLUSIONS: Outcomes were better for patients transplanted in first complete remission than in second complete remission or a more advanced phase of the disease.
  • When a syngeneic donor is available for patients with high risk acute leukemia, allotransplantation should be performed as soon as the first complete remission has been achieved, ideally with one course of chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Diseases in Twins. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Recurrence. Remission Induction. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Jun;93(6):801-5 [18515876.001]
  • (PMID = 18469352.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


62. Zhu YL, Liu J, Zhu P, DU JW, Zhang Y, Gu JY: [Expression of PRAME gene in acute leukemia and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec;15(6):1144-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of PRAME gene in acute leukemia and its clinical significance].
  • This study was aimed to detect the expression levels of preferentially expressed antigen of melanoma (PRAME) gene in acute leukemia (AL) and to evaluate the clinical significance of PRAME gene.
  • The quantitative detection method was established by SYBR Green I real-time quantitative RT-PCR, then PRAME mRNA was measured by this method in 55 cases of acute leukemia, out of which 43 cases were acute myeloid leukemia (AML), 9 cases were acute lymphocytic leukemia (ALL) and other types leukemia were 3 cases.
  • The results showed that the expression of PRAME gene was found in 35 cases of acute leukemia, the positive percentage was 64%.
  • The expression of PRAME gene decreased or disappeared in 6 patients achieving complete remission (CR).
  • There is remarkable difference in the level of PRAME transcript of the 35 cases and the expression of PRAME gene decreases or disappears when the patients achieved complete remission.
  • These results suggest that PRAME expression in acute leukemia may be a useful marker to detect the minimal resi-dual disease (MRD) and to determine the response to therapy in AL patients.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088454.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / PRAME protein, human; 0 / RNA, Messenger
  •  go-up   go-down


63. Gökbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Semin Hematol; 2009 Jan;46(1):64-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of adult acute lymphoblastic leukemia.
  • Treatment results in adult acute lymphoblastic leukemia (ALL) have improved considerably in the past decade, with an increase of complete remission rates to 85% to 90% and overall survival rates to 40% to 50%.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Age Factors. Clinical Trials as Topic. Humans. Pharmacogenetics. Prognosis. Risk Factors. Stem Cell Transplantation


64. Monreal MB, Pardo ML, Pavlovsky MA, Fernandez I, Corrado CS, Giere I, Sapia S, Pavlovsky S: Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia. Cytometry B Clin Cytom; 2006 Mar;70(2):63-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed the expression of CD38 and HLA-DR on CD34+ cells by flow cytometry in 36 patients with MDS, as well as in healthy donors (n = 12) and patients with other hematological disorders: non-Hodgkin lymphomas and multiple myeloma, both in complete remission (CR) (n = 32); acute lymphoblastic leukemia in CR (n = 17); de novo acute myeloblastic leukemia (AML) at diagnosis (n = 22) and in CR (n = 37); and AML secondary to MDS at diagnosis (n = 19).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Disease Progression. Female. Flow Cytometry. HLA-DR Antigens / immunology. Humans. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / immunology. Male. Middle Aged. Multiple Myeloma / diagnosis. Multiple Myeloma / immunology. Observer Variation. Phenotype. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Prognosis. Reproducibility of Results. Risk Factors

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 International Society for Analytical Cytology.
  • (PMID = 16470534.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / HLA-DR Antigens; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


65. Marks DI, Forman SJ, Blume KG, Pérez WS, Weisdorf DJ, Keating A, Gale RP, Cairo MS, Copelan EA, Horan JT, Lazarus HM, Litzow MR, McCarthy PL, Schultz KR, Smith DD, Trigg ME, Zhang MJ, Horowitz MM: A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant; 2006 Apr;12(4):438-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.
  • We compared the outcomes of 298 patients with acute lymphoblastic leukemia in first or second complete remission (CR1 or CR2) receiving HLA-matched sibling allografts after cyclophosphamide and total body irradiation (Cy-TBI) conditioning with 204 patients receiving etoposide and TBI.
  • Analyses of relapse, leukemia-free survival (LFS), and survival were performed separately for CR1 and CR2 transplantations.
  • We conclude that for HLA-identical sibling allografts for acute lymphoblastic leukemia in CR2, there is an advantage in substituting etoposide for Cy or, when Cy is used, in increasing the TBI dose to > or =13 Gy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Hematopoietic Stem Cell Transplantation. Myeloablative Agonists / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Prospective Studies. Remission Induction. Siblings. Survival Rate. Transplantation, Homologous. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545728.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Myeloablative Agonists; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


66. Yoshimitsu M, Fujiwara H, Ozaki A, Hamada H, Matsushita K, Arima N, Tei C: Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. Int J Hematol; 2008 Oct;88(3):331-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions.
  • A 23-year-old man with Philadelphia-chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) from his HLA-identical brother in first hematological remission following induction chemotherapy which included imatinib.
  • He had no acute graft-versus-host disease (GVHD), and 4.5 months after HSCT, he had a molecular relapse (180,000 copies/mug RNA of minor bcr/abl transcripts (m-bcr/abl) without mutation in 22 sites including the p-loop region).
  • At the time of this report, he remains in complete hematological remission more than 33 months after allo-HSCT and persists in the second molecular remission for longer than 24 months.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Living Donors. Lymphocyte Transfusion. Philadelphia Chromosome. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Protein Kinase Inhibitors / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Benzamides. Cyclosporine / administration & dosage. Humans. Imatinib Mesylate. Male. Remission Induction. Siblings. Transplantation, Homologous


67. Xu W, Li JY, Wu YJ, Sheng RL, Lu FX: [Expression of Ki-67 and Bcl-2 in adults and children with acute lymphoblastic leukemia and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):887-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of Ki-67 and Bcl-2 in adults and children with acute lymphoblastic leukemia and its clinical significance].
  • To evaluate the expressions of proliferative antigen Ki-67 and apoptosis-antagonizing protein Bcl-2 as well as their clinical significance, immunohistochemistry staining with SAP was used to detect Ki-67 antigen and Bcl-2 protein in 18 cases of children with acute lymphoblastic leukemia (ALL) and 43 cases of adults with ALL.
  • The highest complete remission rate (CR) was seen in the group with lower expression of both indexes (Ki-67 and Bcl-2).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096882.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


68. Zheng JF, Qiu HY, Pan JL, Cen JN, Wu YF, Zhang J, Wu DP, Xue YQ: [A clinical and laboratory study of TCF3-PBX1 positive adult acute lymphoblastic leukemia.]. Zhonghua Xue Ye Xue Za Zhi; 2010 Jan;31(1):16-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical and laboratory study of TCF3-PBX1 positive adult acute lymphoblastic leukemia.].
  • OBJECTIVE: To explore the morphology, immunophenotype, cytogenetics and clinical features of TCF3-PBX1 fusion gene positive adult acute lymphoblastic leukemia (ALL).
  • RESULTS: The incidence of 19 TCF3-PBX1-positive adult ALL was 3.13% of total ALL patients.
  • Of 18 patients received chemotherapy, 17 (94.7%) achieved complete remission (CR); the median relapse-free survival (RFS) and median overall survival was 3.2 months and 7.2 months, respectively.
  • CONCLUSIONS: TCF3-PBX1-positive adult ALL had unique clinical and pathological features with high remission rate, high relapse rate and short survival time and should be considered to receive intensified treatment strategies. iFISH combined with CC and RT-PCR can increase the detection rate of t(1;19)/TCF3-PBX1 fusion gene.
  • [MeSH-major] Oncogene Proteins, Fusion. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 1. Humans. In Situ Hybridization, Fluorescence. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302770.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


69. Liu J, Wu DS, Zhang S, Yan CH, Zhou Y, Zhang YD, Qi ZH: [Relation between the expression of sIL-2R and the relapse in patients with acute lymphoblastic leukemia]. Beijing Da Xue Xue Bao; 2005 Jun 18;37(3):249-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relation between the expression of sIL-2R and the relapse in patients with acute lymphoblastic leukemia].
  • OBJECTIVE: To explore the relation of the serum level of sIL-2R in relapse patients with acute lymphoblastic leukemia (ALL).
  • METHODS: With ELISA, we determined the levels of sIL-2R of 48 patients with ALL after their first diagnoses, complete remission 1 and relapse.
  • The levels of sIL-2R of 30 patients from complete remission 1 to relapse were monitored.
  • The levels of sIL-2R were higher in the relapse group and first diagnosed group than in the complete remission 1 group.
  • However, the difference between the complete remission 1 and the control had no statistical significance.
  • When we determined the levels of sIL-2R dynamically, we found that after complete remission, the levels of sIL-2R decreased, however, before one month of hematological relapse, the levels of sIL-2R increased.
  • [MeSH-major] Neoplasm Recurrence, Local / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Receptors, Interleukin-2 / blood
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968312.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-2
  •  go-up   go-down


70. Koharazawa H, Kanamori H, Sakai R, Hashimoto C, Takemura S, Hattori M, Taguchi J, Fujimaki K, Tomita N, Fujita H, Fujisawa S, Harano H, Ogawa K, Motomura S, Maruta A, Ishigatsubo Y: Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia. Leuk Lymphoma; 2008 Nov;49(11):2133-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia.
  • We analysed the long-term outcome of the L86 protocol using L-asparaginase (L-asp), vincristine (VCR) and prednisolone (PSL), collectively known as LVP or L97 protocol using LVP along with pirarubicin hydrochloride (THP-ADR) for 97 patients with acute lymphoblastic leukemia (ALL) diagnosed between 1986 and 2002.
  • No significant differences were seen in the two protocols regarding the complete remission (CR) rate or survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Asparaginase / administration & dosage. Female. Humans. Longitudinal Studies. Male. Middle Aged. Philadelphia Chromosome. Prednisolone / administration & dosage. Prognosis. Remission Induction. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021056.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


71. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H: First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood; 2010 Sep 23;116(12):2070-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
  • The combination of cytotoxic chemotherapy and imatinib has improved the outcome for patients with Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL).
  • Patients in complete remission received maintenance daily dasatinib and monthly vincristine and prednisone for 2 years, followed by dasatinib indefinitely.
  • Thirty-five patients with untreated Ph(+) ALL with a median age of 53 years (range, 21-79 years) were treated; 33 patients (94%) achieved complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Thiazoles / administration & dosage
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Dasatinib. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Remission Induction. Survival Analysis. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Nov 1;96(9):3195-9 [11050003.001]
  • [Cites] Blood. 2009 Jul 9;114(2):261-3 [19414863.001]
  • [Cites] Blood. 2001 Apr 1;97(7):1999-2007 [11264164.001]
  • [Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]
  • [Cites] Lancet. 2002 Feb 9;359(9305):487-91 [11853795.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):117-25 [12204532.001]
  • [Cites] Blood. 2003 Jan 15;101(2):690-8 [12509383.001]
  • [Cites] Blood. 2003 Jul 15;102(2):659-61 [12663457.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):96-103 [14657955.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Science. 2004 Jul 16;305(5682):399-401 [15256671.001]
  • [Cites] Leukemia. 1999 Apr;13(4):558-67 [10214862.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3507-12 [15315963.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3739-45 [15315971.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Leukemia. 2005 Apr;19(4):628-35 [15744351.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Semin Hematol. 2006 Apr;43(2):126-33 [16616046.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] Blood. 2006 Jul 15;108(2):697-704 [16597591.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7374-9 [17189410.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] Cancer. 2007 May 15;109(10):2068-76 [17429836.001]
  • [Cites] Blood. 2007 Jul 15;110(2):727-34 [17405907.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3908-14 [17761974.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2309-15 [17496201.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3204-12 [18541900.001]
  • [Cites] Blood. 2008 Aug 1;112(3):903-9 [18519812.001]
  • [Cites] Cancer. 2008 Sep 1;113(5):985-94 [18615627.001]
  • [Cites] Immunol Res. 2008;42(1-3):84-105 [18716718.001]
  • [Cites] Blood. 2009 May 7;113(19):4489-96 [19244158.001]
  • [Cites] Cancer. 2009 Jun 1;115(11):2482-90 [19280591.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6322-9 [19369231.001]
  • [Cites] Leukemia. 2001 Mar;15(3):342-7 [11237055.001]
  • (PMID = 20466853.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00390793
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrimidines; 0 / Thiazoles; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RBZ1571X5H / Dasatinib; CVAD protocol
  • [Other-IDs] NLM/ PMC4081177
  •  go-up   go-down


72. Han Y, Xue Y, Zhang J, Wu Y, Pan J, Wang Y, Shen J, Dai H, Bai S: Translocation (14;14)(q11;q32) with simultaneous involvement of the IGH and CEBPE genes in B-lineage acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2008 Dec;187(2):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (14;14)(q11;q32) with simultaneous involvement of the IGH and CEBPE genes in B-lineage acute lymphoblastic leukemia.
  • However, t(14;14)(q11;q32) is an exceedingly rare phenomenon in B-lineage acute lymphoblastic leukemia (B-ALL).
  • After chemotherapy, the patient achieved complete remission (CR).
  • [MeSH-major] CCAAT-Enhancer-Binding Proteins / genetics. Chromosomes, Human, Pair 14 / genetics. Immunoglobulin Heavy Chains / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / genetics. Daunorubicin / therapeutic use. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Prednisone / therapeutic use. Trisomy. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027493.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCAAT-Enhancer-Binding Proteins; 0 / Immunoglobulin Heavy Chains; 142805-41-2 / CEBPE protein, human; 5J49Q6B70F / Vincristine; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; VDP protocol
  •  go-up   go-down


73. Fujisawa S, Nakamura S, Naito K, Kobayashi M, Ohnishi K: A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: case report and review of the literature. Int J Hematol; 2008 Mar;87(2):184-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: case report and review of the literature.
  • We report a rare case of adult Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) with an e1a3 fusion transcript.
  • She was diagnosed with Ph-positive precursor B cell ALL.
  • She received bone marrow transplantation (BMT) in the first complete remission (CR).
  • The literature on Ph-positive leukemia lacking ABL exon 2 was also reviewed.
  • [MeSH-major] Genes, abl / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Child, Preschool. Exons / genetics. Female. Humans. Infant. Male. Middle Aged. Philadelphia Chromosome. Transcription, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hematol. 2003 Dec;74(4):268-72 [14635208.001]
  • [Cites] Leukemia. 1998 Dec;12(12):1881-5 [9844918.001]
  • [Cites] Leukemia. 1990 Jun;4(6):397-403 [2193202.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1696-702 [7934165.001]
  • [Cites] Br J Haematol. 1993 Dec;85(4):823-5 [7918054.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2291-9 [12613515.001]
  • [Cites] Br J Haematol. 2001 Sep;114(3):635-7 [11552990.001]
  • [Cites] J Exp Med. 1999 Apr 19;189(8):1229-42 [10209040.001]
  • [Cites] Acta Haematol. 2002;108(3):150-3 [12373087.001]
  • [Cites] Transl Res. 2006 Nov;148(5):249-56 [17145570.001]
  • [Cites] Blood. 2000 Jun 15;95(12):4019-20 [10939800.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1092-3 [12130477.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1791 [7934177.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jan 15;116(2):166-9 [10640151.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1109-11 [11167748.001]
  • [Cites] Leukemia. 1999 Sep;13(9):1463-4 [10483000.001]
  • [Cites] Leukemia. 1991 Jun;5(6):457-61 [2056770.001]
  • [Cites] Leukemia. 1998 Feb;12(2):250 [9519792.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Apr 15;174(2):111-5 [17452251.001]
  • [Cites] Blood. 1998 Jan 15;91(2):406-18 [9427693.001]
  • [Cites] Haematologica. 1999 Jun;84(6):573-5 [10366813.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2375-84 [8839828.001]
  • [Cites] Am J Hematol. 2004 Feb;75(2):92-5 [14755375.001]
  • [Cites] Leukemia. 1993 Oct;7(10):1504-8 [8412311.001]
  • (PMID = 18253707.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 25
  •  go-up   go-down


74. Parovichnikova EN, Savchenko VG, Verniuk MA, Vinogradova OA, Misiurin AV, Vorob'ev IA, Domracheva EV, Tikhonova LIu, Rukavitsyn OA, Rossiev VA, Kliasova GA, Turkina AG, Liubimova LS, Mendeleeva LP, Isaev VG: [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes]. Ter Arkh; 2005;77(7):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes].
  • AIM: To develop an original therapeutic strategy in Ph-positive acute lymphoblastic leukemia (ALL).
  • Complete hematological remissions were achieved in the majority of the patients (6 of 8) irrespective of imatinib administration.
  • Achievement of molecular remission in BCR-ABL-positive ALL occurs also in standard chemotherapy but molecular remissions begin 2-4 months later than clinicohematological ones.
  • CONCLUSION: In using imatinib combination with chemotherapy, molecular remission can be achieved simultaneously with hematological one.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Benzamides. Female. Follow-Up Studies. Humans. Imatinib Mesylate. In Situ Hybridization, Fluorescence. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Remission Induction. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116902.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


75. Morimoto A, Imamura T, Ishii R, Nakabayashi Y, Nakatani T, Sakagami J, Yamagami T: Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic. Cancer; 2008 Sep 15;113(6):1362-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: L-asparaginase is a key drug in the treatment of childhood acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).
  • Significantly, chemotherapy could be resumed within 4 weeks (range, 12-23 days) after the onset of AAP, and the patients were in complete remission from 4 months to 44 months with further chemotherapy that excluded L-asparaginase.
  • [MeSH-minor] Child. Child, Preschool. Drug Therapy, Combination. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Neoplasm Recurrence, Local / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18661511.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 0 / Protease Inhibitors; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


76. Baldus CD, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M, Burmeister T, Schwartz S, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK: Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica; 2009 Oct;94(10):1383-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.
  • BACKGROUND: NOTCH1 mutations have been associated with a favorable outcome in pediatric acute T-lymphoblastic leukemia.
  • However, the results of studies on the prognostic significance of NOTCH1 mutations in adult T-lymphoblastic leukemia remain controversial.
  • DESIGN AND METHODS: Here we have investigated the prognostic impact of mutations in the NOTCH1 pathway, in particular, the NOTCH1 and FBXW7 genes, in a large cohort of adult patients with T-lymphoblastic leukemia (n=126).
  • In the overall cohort, no significant differences were seen in the complete remission or event-free survival rates between patients with mutated or wild-type NOTCH1-FBXW7 (p=0.39).
  • CONCLUSIONS: NOTCH1 and FBXW7 mutations were not predictive of outcome in the overall cohort of adult patients with T-lymphoblastic leukemia, but there was a trend towards a favorable prognostic impact of NOTCH1-FBXW7 mutations in the small subgroup of patients with low-risk ERG/BAALC expression status.
  • Our findings further confirm the high frequency of NOTCH1 mutations in adult T-lymphoblastic leukemia.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate / trends. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Sep 21;276(38):35847-53 [11461910.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Semin Cell Dev Biol. 2005 Jun;16(3):323-33 [15840441.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1841-3 [16079893.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4714-20 [16954520.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:169-77 [17124057.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1879-82 [17332312.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] J Exp Med. 2007 Nov 26;204(12):2875-88 [17984302.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]
  • [Cites] Leukemia. 2008 Jan;22(1):124-31 [17928886.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1154-60 [18368072.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [CommentIn] Haematologica. 2009 Oct;94(10):1338-40 [19794079.001]
  • (PMID = 19794083.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Receptor, Notch1; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC2754954
  •  go-up   go-down


77. Song HH, Chen BA, Ding JH, Sun XM, Gao C, Sun YY, Wang J, Cheng J, Zhao G: [Effect of hematopoietic stem cell transplantation in malignant hematologic disease of lymphatic system]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):945-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Through observing 8 patients with non-Hodgkin's lymphoma (NHL) and 3 patients with lymphoblastic leukemia, who received auto or allo-HSCT after chemotherapy, the hematopoietic reconstitution, complication and survival time were evaluated.
  • The results showed that 11 patients (7 patients after auto-PBSCT, 4 patients after allo-PBSCT) all achieved hematopoietic reconstitution and complete remission (CR).
  • From 4 cases received allo-PBSCT, one patient with NHL (NK cell) was died at 79 days later, one patient with chronic lymphoblastic leukemia was surviving, another 2 cases of acute lymphoblastic leukemia were dead at 17 months and 54 days respectively after allo-PBSCT.

  • Genetic Alliance. consumer health - Lymphatic Disease.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096894.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


78. van Beek RD, de Muinck Keizer-Schrama SM, Hakvoort-Cammel FG, van der Sluis IM, Krenning EP, Pieters R, van den Heuvel-Eibrink MM: No difference between prednisolone and dexamethasone treatment in bone mineral density and growth in long term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2006 Jan;46(1):88-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No difference between prednisolone and dexamethasone treatment in bone mineral density and growth in long term survivors of childhood acute lymphoblastic leukemia.
  • In this study, we compared the long-term effects of dexamethasone and prednisolone on bone mineral density (BMD), body composition and growth in long-term survivors of ALL in first complete remission.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Bone Density / drug effects. Dexamethasone / pharmacology. Growth / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisolone / pharmacology. Survivors
  • [MeSH-minor] Adolescent. Adult. Body Composition. Child. Child, Preschool. Cross-Sectional Studies. Female. Fractures, Bone / epidemiology. Humans. Infant. Male. Netherlands / epidemiology. Regression Analysis


79. Merkle M, Rupprecht HD: [Lymphoproliferative disease following kidney transplantation]. Dtsch Med Wochenschr; 2005 Jul 15;130(28-29):1691-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 4 chemotherapy cycles the patient was in complete remission and another 2 therapy cycles were given for consolidation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Kidney Transplantation / adverse effects. Lymphoma, B-Cell / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Abdominal Pain. Adult. Diagnosis, Differential. Diarrhea. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Male. Remission Induction. Risk Factors


80. Gong H, Liu WL, Zhou JF, Xu HZ: [Expression of mitosis checkpoint gene CHFR in acute leukemia]. Zhonghua Yi Xue Za Zhi; 2005 Apr 27;85(16):1085-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of mitosis checkpoint gene CHFR in acute leukemia].
  • OBJECTIVE: To investigate the expression of mitosis checkpoint gene CHFR in adult patients with acute leukemia (AL) and its clinical significance.
  • METHODS: Four ml of bone marrow was extracted from 65 AL patients, 38 males and 27 females, with the median age of 35, 43 with acute myelocytic leukemia (AML) and 22 with acute lymphocytic leukemia (ALL), 45 de novo patients and 20 recurrent patients, and 8 normal donor of allogeneic bone marrow transplantation as controls.
  • (1) The levels of CHFR protein and mRNA were correlated with the cumulative percentages of cells in S phases. (2) The expression level of CHFR protein in 40.6% (13/32) of the AL patients and that of the CHFR mRNA in 60.0% (27/45) of the AL patients were both significantly lower than those of the normal controls. (3) The mean expression level of CHFR protein in the recurrent acute lymphoblastic leukemia (ALL) was 0.71, significantly higher than that of the de novo group (0.38, t = 2.54, P = 0.017). (4) The complete remission (CR) rates in the AL patients with high expression levels of CHFR protein and mRNA were 30.2% and 42.4% respectively, significantly lower than those in the AL patients with low expression levels (88.6% and 85.4% respectively, both P < 0.05).
  • CONCLUSION: By affecting mitotic checkpoint function, CHFR inactivation plays a key role in tumorigenesis in adult patients with acute leukemia.
  • Moreover, the aberrant expression of CHFR appears to be a good molecular marker to predict the sensitivity of acute leukemia to chemotherapy.
  • [MeSH-major] Cell Cycle Proteins / biosynthesis. Leukemia, Myeloid, Acute / genetics. Neoplasm Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / pharmacology. Cell Cycle. Child. Drug Resistance. Female. HL-60 Cells. Humans. Male. Middle Aged. Mitosis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029562.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CHFR protein, human; 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


81. Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G: XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer; 2010 Aug;55(2):260-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Resistance to glucocorticoid induced apoptosis is one of the major risk factors for relapse and poor outcome in childhood acute lymphoblastic leukemia (ALL).
  • Similarly, T-cell ALL patients suffering adverse events showed higher initial XIAP levels than patients in continuous complete remission (CCR) (median: 2.7 in patients in CCR vs. 5.6 in patients suffering adverse events; P = 0.007).
  • [MeSH-major] Gene Expression Regulation, Leukemic. Glucocorticoids / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. X-Linked Inhibitor of Apoptosis Protein / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Bone Marrow Cells / pathology. Bone Marrow Examination. Child. Drug Resistance. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Monocytes / pathology. Pharmacogenetics. Prognosis. RNA, Messenger / analysis. Treatment Outcome. Up-Regulation


82. Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, Shiramizu B, Wiley J, Woods D, Barnich M, Gross TG, Children's Oncology Group: A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer; 2009 Feb;52(2):177-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
  • BACKGROUND: To estimate the response rate and therapy related toxicities of the anti-CD20 monoclonal antibody rituximab when combined with chemotherapy including ifosfamide, carboplatin, and etoposide (ICE) in patients with relapsed and refractory B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia (B-ALL).
  • Of the six eligible patients with diffuse large B-cell lymphoma, three achieved complete remission (CR), one had stable disease (SD), and two had progressive disease (PD).
  • Of the 14 eligible patients with Burkitt lymphoma and B-ALL, there were four complete responses (CR), five partial responses (PR), one SD, and four with PD.


83. Cho YU, Park CJ, Cha CH, Chi HS, Jang S, Kim MJ, Lee KH, Lee JH, Lee JH, Seo JJ, Im HJ: [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression]. Korean J Lab Med; 2010 Dec;30(6):533-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression].
  • BACKGROUND: It has been demonstrated that flow cytometric detection of minimal residual disease (MRD) has a prognostic significance in the treatment of patients with acute leukemia.
  • METHODS: We analyzed the results of MRD detection in morphologically complete remission bone marrow aspirates from 89 patients with newly-diagnosed or relapsed acute leukemia, in which leukemic cells had cross-lineage antigen expression.
  • [MeSH-major] Antigens / metabolism. Flow Cytometry. Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antigens, CD / metabolism. Bone Marrow / metabolism. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Neoplasm, Residual / diagnosis. Recurrence. Survival Rate

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157135.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, CD
  •  go-up   go-down


84. Labar B, Suciu S, Willemze R, Muus P, Marie JP, Fillet G, Berneman Z, Jaksic B, Feremans W, Bron D, Sinnige H, Mistrik M, Vreugdenhil G, De Bock R, Nemet D, Gilotay C, Amadori S, de Witte T, EORTC Leukemia Group: Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica; 2010 Sep;95(9):1489-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.
  • BACKGROUND: Corticosteroids are a standard component of the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.
  • DESIGN AND METHODS: Adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma were randomized to receive, as part of their induction therapy on days 1-8 and 15-22, either dexamethasone 8 mg/m(2) or prednisolone 60 mg/m(2).
  • Those who reached complete remission were given two courses of consolidation therapy with high-dose cytarabine and mitoxantrone and methotrexate and asparaginase.
  • After induction and the course of first consolidation therapy, 131 (80.4%) patients in the dexamethasone group and 124 (76.5%) in the prednisolone group achieved complete remission.
  • Disease-free survival after complete remission was also similar in the dexamethasone and prednisolone groups, the 6-year rates being 32.3% and 37.5%, respectively (hazard ratio 1.03; 95% confidence interval 0.76-1.40).
  • CONCLUSIONS: In the ALL-4 trial in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, treatment with dexamethasone did not show any advantage over treatment with prednisolone.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1986 Mar 20;314(12):729-35 [3513012.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Jun;40(6):1073-7 [1133157.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):269-75 [2056971.001]
  • [Cites] Bone Marrow Transplant. 1994 Nov;14(5):767-74 [7889010.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):1-12 [7743230.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):911-8 [8622039.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):114-21 [8649318.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2370-6 [8708730.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Leukemia. 2007 Apr;21(4):593-4 [17301807.001]
  • [Cites] Semin Hematol. 2007 Oct;44(4):267-73 [17961726.001]
  • [Cites] Health Qual Life Outcomes. 2008;6:103 [19036151.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec;53(6):984-91 [19621425.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Leukemia. 2000 Mar;14(3):356-63 [10720126.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1964-9 [10760775.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2193-4 [11187910.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Apr-May;18(3):187-91 [11293286.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2898-903 [12767105.001]
  • [Cites] Haematologica. 2004 Jul;89(7):809-17 [15257932.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):202-7 [3806166.001]
  • (PMID = 20378563.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / CA11488-25; United States / NCI NIH HHS / CA / CA11489-39
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone
  • [Other-IDs] NLM/ PMC2930949
  •  go-up   go-down


85. Kawabata Y, Hirokawa M, Saitoh Y, Kosugi S, Yoshioka T, Fujishima M, Fujishima N, Kameoka Y, Saitoh H, Kume M, Takahashi N, Sawada K: Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia. Int J Hematol; 2006 Dec;84(5):445-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia.
  • A 43-year-old Japanese woman underwent unrelated cord blood transplantation (CBT) during remission for acute lymphoblastic leukemia with t(4; 11)(q21;q23).
  • The posttransplantation clinical course was mostly uneventful, and the leukemia remained in remission.
  • Although the patient showed complete donor-type hematopoiesis, the titer of viral capsid antigen immunoglobulin G was low, and the results of a test for EBV nuclear antigen were negative.
  • [MeSH-major] Epstein-Barr Virus Infections. Hemorrhage. Herpesvirus 4, Human. Lymphohistiocytosis, Hemophagocytic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Acyclovir / administration & dosage. Adult. Anti-Inflammatory Agents / administration & dosage. Antibodies, Viral / blood. Antiviral Agents / administration & dosage. Bone Marrow Diseases / blood. Bone Marrow Diseases / drug therapy. Bone Marrow Diseases / etiology. Bone Marrow Diseases / virology. Epstein-Barr Virus Nuclear Antigens / blood. Female. Hematopoiesis. Humans. Immunoglobulin G / blood. Liver Failure / blood. Liver Failure / drug therapy. Liver Failure / etiology. Liver Failure / virology. Methylprednisolone / administration & dosage. Time Factors. Transplantation Chimera


86. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J, O'Brien S: Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma; 2010 Mar;51(3):475-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission.
  • The outcome of adults with acute lymphocytic leukemia (ALL) who achieve a complete response (CR) on salvage therapy is thought to be poor, but not previously analyzed.
  • To define the course of adult ALL post CR on salvage therapy and the effects of pretreatment factors on prognosis.
  • This analysis defines the outcome of adult ALL in CR post salvage therapy and the prognostic factors influencing survival.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Humans. Middle Aged. Prognosis. Remission Induction. Risk Factors. Salvage Therapy. Survival Analysis. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1327-52 [11147226.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1353-66, x [11147227.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1367-79, x [11147228.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205 [11253606.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1216-30 [10506707.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Feb;7(2):113-8 [17288522.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5136-42 [17344466.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1907-14 [17611565.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2309-15 [17496201.001]
  • (PMID = 20078325.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS596181; NLM/ PMC4086446
  •  go-up   go-down


87. Fischer L, Gökbuget N, Schwartz S, Burmeister T, Rieder H, Brüggemann M, Hoelzer D, Thiel E: CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy. Haematologica; 2009 Feb;94(2):224-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy.
  • BACKGROUND: Expression of CD56 has been associated with poor prognosis in acute myeloid leukemia and aggressive lymphoma.
  • DESIGN AND METHODS: We analyzed the impact of CD56 expression in a cohort of 452 newly diagnosed adult T-cell acute lymphoblastic leukemia (T-ALL) patients; clinical data were available for 306 patients.
  • Treatment of CD56(+) ALL resulted in a lower rate of complete remissions (70% vs. 88%) (p=0.001) and a higher rate of resistant disease (21% vs. 8%) (p=0.004).
  • CONCLUSIONS: CD56 is expressed on a subset of adult T-ALL with distinct immunophenotypical features and higher resistance to therapy.
  • [MeSH-major] Antigens, CD56. Drug Resistance, Neoplasm. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Female. Humans. Male. Middle Aged. Phenotype. Prognosis. Remission Induction / methods. Survival Analysis. Young Adult


88. Bao L, Jiang B, Huang XJ, Wang DB, Qiu JY, Lu XJ, Chen H, Lu DP: [Clinical study of Philadelphia chromosome-positive acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2005 Jan;26(1):31-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of Philadelphia chromosome-positive acute lymphoblastic leukemia].
  • OBJECTIVE: To study the clinical characteristics and therapeutic outcome of Ph+ acute lymphoblastic leukemia (ALL).
  • The chemotherapy complete remission rate was 68.8% in patients with only Ph+ versus 28.6% in those with additional chromosome abnormalities.
  • The total complete remission rate was 73.3% in all Ph+ ALL patients.
  • The median remission duration was shorter in patients with additional chromosome than in those with only Ph+ (1 vs 7 months, P < 0.05), and so was the survival period (7 vs 9 months, P > 0.05).
  • The remission duration was significantly longer in patients received allo-HSCT than in those received chemotherapy only (8 vs 0.5 month, P < 0.05), and so was the survival period (12.5 vs 6 months, P < 0.05).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946506.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


89. Gandemer V, Auclerc MF, Perel Y, Vannier JP, Le Gall E, Demeocq F, Schmitt C, Piguet C, Stephan JL, Lejars O, Debre M, Jonveaux P, Cayuela JM, Chevret S, Leverger G, Baruchel A, FRALLE group: Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study. BMC Cancer; 2009;9:14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.
  • BACKGROUND: We explored the heterogeneity of philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL) in a study of the effect of early features on prognosis in children.
  • RESULTS: Complete remission (CR) was observed in 26 children (72%), of which 13 underwent allogeneic bone marrow transplantation (BMT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Bone Marrow / drug effects. Leukocyte Count. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Acute Disease. Adolescent. Age Factors. Anthracyclines. Asparaginase. Benzamides. Bone Marrow Transplantation. Child. Child, Preschool. Cortisone. Female. Humans. Imatinib Mesylate. Infant. Male. Prednisone / administration & dosage. Recurrence. Treatment Outcome. Vincristine. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Apr;19(4):628-35 [15744351.001]
  • [Cites] Br J Haematol. 2005 Apr;129(1):35-44 [15801953.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1341-9 [17312329.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2791-3 [17119111.001]
  • [Cites] Haematologica. 2007 Dec;92(12):1723-4 [18056006.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):447-53 [17968326.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1496-503 [18349402.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1700-6 [12970767.001]
  • [Cites] Bone Marrow Transplant. 2004 Jan;33(1):39-45 [14566329.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1043-9 [14525776.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1292-5 [7632935.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1493-6 [9305603.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7209-19 [16243790.001]
  • (PMID = 19144139.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 5J49Q6B70F / Vincristine; 8A1O1M485B / Imatinib Mesylate; EC 3.5.1.1 / Asparaginase; V27W9254FZ / Cortisone; VB0R961HZT / Prednisone; FRALLE 93 protocol
  • [Other-IDs] NLM/ PMC2629767
  • [Investigator] Pautard B; Bauduer JF; Abgrall JF; Berthou C; Paillard C; Kanold J; Couillault G; Damay M; de Lumley L; Michel G; Thuret I; Chambost H; Bordigoni P; Sommel D; Leblanc T; Schaison G; Tabone MD; Donadieu J; Landman-Parker J; Auvrignon A; Thomas C; Fisher A; Dommergues JP; Bader-Meunier B; Bernaudin F; Lemerle S; Choulot J; Doireau V; Edan C; Bergeron C; Schneider P; Lamagnere JP; Berger C; Cornu G; Vermylen C
  •  go-up   go-down


90. Marks DI, Pérez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ: Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood; 2008 Jul 15;112(2):426-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.
  • We report the retrospective outcomes of unrelated donor (URD) transplants in 169 patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) who received transplants between 1995 and 2004.
  • A total of 50% had a white blood cell count (WBC) more than 30 x 10(9)/L, 18% extramedullary disease, 42% achieved CR more than 8 weeks from diagnosis, 25% had adverse cytogenetics, and 19% had T-cell leukemia.
  • At 54-month median follow-up, incidences of acute grade 2-IV, III to IV, and chronic graft-versus-host disease were 50%, 25%, and 43%, respectively.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(6):549-56 [15756282.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58 [18541193.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1572-7 [11238093.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Dec;14(4):793-805 [11924922.001]
  • [Cites] Haematologica. 2003 May;88(5):555-60 [12745275.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1619-28 [7632972.001]
  • [Cites] Bone Marrow Transplant. 1998 Jan;21(2):153-8 [9489632.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):931-6 [9508175.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2236-46 [10498594.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):683-9 [16113673.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):155-63 [16284608.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2657-63 [16703597.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5695-702 [17116940.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2007 Jul 1;110(1):409-17 [17374741.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [CommentIn] Blood. 2008 Jul 15;112(2):212 [18606879.001]
  • [CommentIn] Blood. 2008 Jul 15;112(2):447-8; author reply 448-9 [18606892.001]
  • (PMID = 18398065.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2442751
  •  go-up   go-down


91. Chan MS, Roebuck DJ, Yuen MP, Li CK, Chan YL: MR imaging of the brain in patients cured of acute lymphoblastic leukemia--the value of gradient echo imaging. AJNR Am J Neuroradiol; 2006 Mar;27(3):548-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of the brain in patients cured of acute lymphoblastic leukemia--the value of gradient echo imaging.
  • BACKGROUND AND PURPOSE: Hemosiderin and white matter lesions are 2 of the most common neurologic complications found on MR imaging that may be related to cranial irradiation and intrathecal methotrexate (MTX) therapy in childhood acute lymphoblastic leukemia (ALL).
  • We evaluated the brains of patients previously treated for ALL with cranial irradiation and intrathecal MTX with MR imaging and tested the hypothesis that these patients have more MR evidence of central nervous system (CNS) injury than control patients who are in complete remission following systemic chemotherapy without cranial irradiation.
  • [MeSH-major] Brain / pathology. Magnetic Resonance Imaging. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adolescent. Adult. Antimetabolites, Antineoplastic / administration & dosage. Child. Female. Humans. Injections, Spinal. Male. Methotrexate / administration & dosage. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551991.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


92. Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, Dupriez B, Pigneux A, Choufi B, Reman O, Stéphane D, Royer B, Vigier M, Ojeda-Uribe M, Recher C, Dombret H, Huguet F, Rousselot P, Intergroupe Français des Leucémies Myéloïdes Chronique, Group for Research in Adult Acute Lymphoblastic Leukemia: High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia; 2006 Mar;20(3):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
  • Imatinib combined with high-dose chemotherapy is now becoming the gold standard for treatment of Philadelphia chromosome-positive acute leukemias.
  • Thirty-one patients (18 relapsing or refractory Ph+ acute lymphoblastic leukemias and 13 lymphoid blast crisis chronic myelogenous leukemias) were enrolled.
  • Complete remission (CR) was obtained in 28 out of 30 assessable patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


93. Dhédin N, Dombret H, Thomas X, Lhéritier V, Boiron JM, Rigal-Huguet F, Vey N, Kuentz M, Reman O, Witz F, Delannoy A, Kovacsovics T, Bradstock K, Charrin C, Boucheix C, Gabert J, Blaise D, Fière D, Vernant JP: Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia; 2006 Feb;20(2):336-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials.
  • To evaluate the results of autologous stem cell transplantation (ASCT) in a large population of adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR), we performed an individual data-based overview of the last three trials from the LALA group.
  • [MeSH-major] Peripheral Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Recurrence. Remission Induction. Risk Factors. Survival Analysis. Transplantation, Autologous


94. Han Y, Luo JM, Jia XH, Wang FX, Yao L, DU XY: [Expression and clinical value of SHP-1 and c-kit in acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):867-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical value of SHP-1 and c-kit in acute leukemia].
  • The aim of study is to investigate the expression of hematopoietic cell phosphatase (SHP-1) gene and c-kit pro-oncogene in acute leukemia (AL) and its impact on prognosis in AL.
  • The results showed that the positive rates of SHP-1 expression from high to low level were found orderly in complete remission group, newly diagnosed group and relapsed group, there was significance difference between each group and NC group (P < 0.05).
  • The positive rate of SHP-1 and c-kit expressions in AML was higher than that in ALL (P < 0.05), there was negative correlation between expressions of SHP-1 and c-kit (r = -0.502, P < 0.05); The difference between the complete remission rate in SHP-1 positive and in SHP-1 negative patients from 30 newly diagnosed AML patients was significant (P < 0.05), the same result was found between c-kit(+) complete remission and c-kit(-) complete remission.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096878.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 6
  •  go-up   go-down


95. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, Parody R, Deben G, Bello JL, Feliu E, Programa para el Estudio y Tratamiento de Hemopatias Malignas Group: Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer; 2006 Jun 15;106(12):2540-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
  • Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) confers a poor prognosis, although to the authors' knowledge, only a few studies have analyzed this issue in adults.
  • For the current study, the authors analyzed the frequency, predictive factors, and prognosis of CNS involvement and recurrence in adult patients with ALL who did not receive cranial irradiation for CNS prophylaxis.
  • Four hundred sixty-seven adult patients (age > or = 15 years) with ALL were treated on 4 protocols: ALL-89 (standard-risk and high-risk ALL; n = 108 patients), ALL-93 (high-risk ALL; n = 222 patients), ALL-96 (standard-risk ALL; n = 84 patients), and ALL3-97 (Burkitt leukemia; n = 53 patients).
  • A complete remission was attained in 7 of 22 patients (32%).
  • The frequency of CNS recurrence in adult patients with ALL who do not receive radiotherapy for CNS prophylaxis was similar to the frequency observed in protocols that included cranial irradiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Incidence. Lactate Dehydrogenases / analysis. Male. Methotrexate / administration & dosage. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16700036.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 1.1.- / Lactate Dehydrogenases; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


96. Heesch S, Goekbuget N, Stroux A, Tanchez JO, Schlee C, Burmeister T, Schwartz S, Blau O, Keilholz U, Busse A, Hoelzer D, Thiel E, Hofmann WK, Baldus CD: Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica; 2010 Jun;95(6):942-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.
  • BACKGROUND: The role of the Wilms tumor 1 gene (WT1) in acute leukemias has been underscored by mutations found in acute myeloid leukemia identifying patients with inferior survival.
  • Furthermore, aberrant expression of WT1 in acute myeloid leukemia was associated with an increased risk of relapse.
  • No larger studies have performed a combined approach including WT1 mutation and expression analyses in acute T-lymphoblastic leukemia.
  • DESIGN AND METHODS: We analyzed the WT1 mutations and the expression status in a total of 252 consecutive adult patients with newly diagnosed T-lymphoblastic leukemia, who were registered on the GMALL 06/99 and 07/03 protocols and had sufficient material available.
  • The GMALL protocols included intensive chemotherapy as well as stem cell transplantation according to a risk-based model with indication for stem cell transplantation in first complete remission for early and mature T-lymphoblastic leukemia patients; patients with thymic T-lymphoblastic leukemia were allocated to a standard risk group and treated with intensive chemotherapy.
  • In thymic T-lymphoblastic leukemia, WT1mut patients had an inferior relapse-free survival compared to WT1 wild-type patients.
  • T-lymphoblastic leukemia patients with aberrant WT1 expression (high or negative) showed a higher relapse rate and an inferior outcome compared to patients with intermediate WT1 expression.
  • In the standard risk group of thymic T-lymphoblastic leukemia, aberrant WT1 expression was predictive for an inferior relapse-free survival as compared to patients with intermediate expression.
  • CONCLUSIONS: WT1 mutations were associated with an inferior relapse-free survival in standard risk thymic T-lymphoblastic leukemia patients.
  • Moreover, altered expression associated with inferior outcome also suggests a role of WT1 in T-lymphoblastic leukemia and the potential use of molecularly-based treatment stratification to improve outcome.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, Wilms Tumor / physiology. Mutation / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate / trends. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Leukemia. 1995 Jun;9(6):1060-7 [7596170.001]
  • [Cites] Exp Hematol. 1997 Apr;25(4):312-20 [9131006.001]
  • [Cites] Leukemia. 1997 May;11(5):639-43 [9180285.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1217-25 [9242555.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2961-8 [9531607.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):3990-4003 [10406804.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1416-23 [15920493.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4414-5 [16326981.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]
  • [Cites] Haematologica. 2006 Feb;91(2):270-1 [16461320.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1507-15 [16575000.001]
  • [Cites] Oncogene. 2006 Jul 13;25(30):4217-29 [16518414.001]
  • [Cites] Leukemia. 2007 Mar;21(3):550-1; author reply 552 [17205055.001]
  • [Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]
  • [Cites] Expert Rev Mol Med. 2007;9(14):1-17 [17524167.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Leukemia. 2008 Apr;22(4):762-70 [18185524.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1154-60 [18368072.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1038-45 [19494353.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3303-12 [16380455.001]
  • [Cites] EMBO J. 2001 Apr 17;20(8):1897-909 [11296223.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1914-22 [11753613.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):409-20 [11841446.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):463-70 [12841384.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Haematologica. 2004 Aug;89(8):926-33 [15339675.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1989 Apr;73(5):1247-58 [2467704.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):6198-206 [8119964.001]
  • [Cites] Hum Mutat. 1997;9(3):209-25 [9090524.001]
  • (PMID = 20435628.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2878792
  •  go-up   go-down


97. Or R, Hadar E, Bitan M, Resnick IB